<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Platinum‐containing regimens for metastatic breast cancer - Egger, SJ - 2017 | Cochrane Library</title> <meta content="Platinum‐containing regimens for metastatic breast cancer - Egger, SJ - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003374.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Platinum‐containing regimens for metastatic breast cancer - Egger, SJ - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003374.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003374.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Platinum‐containing regimens for metastatic breast cancer" name="citation_title"/> <meta content="Sam J Egger" name="citation_author"/> <meta content="Cancer Council NSW" name="citation_author_institution"/> <meta content="same@nswcc.org.au" name="citation_author_email"/> <meta content="Melina L Willson" name="citation_author"/> <meta content="NHMRC Clinical Trials Centre, The University of Sydney" name="citation_author_institution"/> <meta content="Jenna Morgan" name="citation_author"/> <meta content="University of Sheffield" name="citation_author_institution"/> <meta content="Harriet S Walker" name="citation_author"/> <meta content="University of Sheffield" name="citation_author_institution"/> <meta content="Sue Carrick" name="citation_author"/> <meta content="Davina Ghersi" name="citation_author"/> <meta content="Nicholas Wilcken" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD003374.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/06/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003374.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003374.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003374.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alopecia [chemically induced, epidemiology]; Anemia [chemically induced]; Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; Breast Neoplasms [*drug therapy, mortality, pathology]; Carboplatin [administration &amp; dosage, adverse effects]; Cisplatin [administration &amp; dosage, adverse effects]; Disease-Free Survival; Leukopenia [chemically induced, epidemiology]; Nausea [chemically induced]; Organoplatinum Compounds [administration &amp; dosage, adverse effects]; Pyridines [administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic; Survival Rate; Triple Negative Breast Neoplasms [drug therapy, mortality, pathology]; Vomiting [chemically induced, epidemiology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003374.pub4&amp;doi=10.1002/14651858.CD003374.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003374\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003374\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ja","hr","de","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003374.pub4",title:"Platinum\\u2010containing regimens for metastatic breast cancer",firstPublishedDate:"Jun 23, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Breast Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003374.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003374.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003374.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003374.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003374.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003374.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003374.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003374.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003374.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003374.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2841 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003374.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/appendices#CD003374-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/table_n/CD003374StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/table_n/CD003374StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Platinum‐containing regimens for metastatic breast cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information#CD003374-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sam J Egger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information#CD003374-cr-0003">Melina L Willson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information#CD003374-cr-0004">Jenna Morgan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information#CD003374-cr-0005">Harriet S Walker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information#CD003374-cr-0006">Sue Carrick</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information#CD003374-cr-0007">Davina Ghersi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information#CD003374-cr-0008">Nicholas Wilcken</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information/en#CD003374-sec-0106">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 June 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003374.pub4">https://doi.org/10.1002/14651858.CD003374.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003374-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003374-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003374-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003374-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003374-abs-0002">日本語</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003374-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003374-abs-0001" lang="en"> <section id="CD003374-sec-0001"> <h3 class="title" id="CD003374-sec-0001">Background</h3> <p>Studies have reported high tumour response rates for platinum‐containing regimens in the treatment of women with metastatic breast cancer. Most of these studies were conducted prior to the 'intrinsic subtype' era, and did not specifically focus on metastatic triple‐negative breast cancers (mTNBCs). </p> </section> <section id="CD003374-sec-0002"> <h3 class="title" id="CD003374-sec-0002">Objectives</h3> <p>To identify and review the evidence from randomised trials comparing platinum‐containing chemotherapy regimens with regimens not containing platinum in the management of women with metastatic breast cancer. </p> </section> <section id="CD003374-sec-0003"> <h3 class="title" id="CD003374-sec-0003">Search methods</h3> <p>For this review update, we searched the Cochrane Breast Cancer Group's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.gov on 28 May 2015. We identified further potentially relevant studies from handsearching references of previous trials, systematic reviews, and meta‐analyses. Prior to this review update, the most recent search for studies was conducted in May 2003 for the original 2004 review. </p> </section> <section id="CD003374-sec-0004"> <h3 class="title" id="CD003374-sec-0004">Selection criteria</h3> <p>Randomised trials comparing platinum‐containing chemotherapy regimens with regimens not containing platinum in women with metastatic breast cancer. </p> </section> <section id="CD003374-sec-0005"> <h3 class="title" id="CD003374-sec-0005">Data collection and analysis</h3> <p>At least two independent reviewers assessed studies for eligibility and quality, and extracted all relevant data from each study. Hazard ratios (HRs) were derived for time‐to‐event outcomes, where possible, and fixed‐effect models were used for meta‐analyses. Objective tumour response rates (OTRRs) and toxicities were analysed as binary (dichotomous) outcomes with risk ratios (RRs) used as measures of effects. Quality of life data were extracted where available. GRADE was used to rate the quality of evidence for survival and tumour response outcomes at the level of subgroups selected and unselected for mTNBC, and for toxicity outcomes based on combining data from selected and unselected populations. </p> </section> <section id="CD003374-sec-0006"> <h3 class="title" id="CD003374-sec-0006">Main results</h3> <p>This update includes 15 new eligible treatment‐comparisons from 12 studies. In total, 28 treatment‐comparisons, involving 4418 women, from 24 studies are now included in one or more meta‐analyses. Of the 28 treatment‐comparisons, 19 and 16 had published or provided extractable time‐to‐event data on overall survival (OS) or progression‐free survival/time to progression (PFS/TTP), respectively. All 28 treatment‐comparisons provided OTRR data that could be included in meta‐analyses. Most women recruited to the studies were not selected on the basis of mTNBC status. </p> <p>In a subgroup of three treatment‐comparisons assessing women with mTNBC, platinum‐containing regimens may have provided a survival benefit (HR 0.75, 95% CI 0.57 to 1.00; low‐quality evidence). In women unselected for intrinsic subtypes such as mTNBC, there was little or no effect on survival (HR 1.01, 95% CI 0.92 to 1.12; high‐quality evidence). This effect was similar to the combined analysis of survival data for both populations (HR 0.98, 95% CI 0.89 to 1.07; I<sup>2</sup> =39%, 1868 deaths, 2922 women; 19 trials). The difference in treatment effects between mTNBC women compared with unselected women was of borderline statistical significance (P = 0.05). </p> <p>Data from three treatment‐comparisons with mTNBC participants showed that platinum regimens may improve PFS/TTP (HR 0.59, 95% CI 0.49 to 0.72; low‐quality evidence). Thirteen treatment‐comparisons of unselected metastatic participants showed that there was probably a small PFS/TTP benefit for platinum recipients, although the confidence interval included no difference (HR 0.92, 95% CI 0.84 to 1.01; moderate‐quality evidence). Combined analysis of data from an estimated 1772 women who progressed or died out of 2136 women selected or unselected for mTNBC indicated that platinum‐containing regimens improved PFS/TTP (HR 0.85, 95% CI 0.78 to 0.93). There was marked evidence of heterogeneity (P = 0.0004; I<sup>2</sup> = 63%). The larger treatment benefit in mTNBC women compared with unselected women was statistically significant (P &lt; 0.0001). </p> <p>There was low‐quality evidence of better tumour response in both subgroups of women with mTNBC and unselected women (RR 1.33, 95% CI 1.13 to 1.56; RR 1.11, 95% CI 1.04 to 1.19, respectively). Combined analysis of both populations was closer to the effect in unselected women (RR 1.15, 95% CI 1.08 to 1.22; 4130 women). There was considerable evidence of heterogeneity (P &lt; 0.0001; I<sup>2</sup> = 64%), which may reflect between‐study differences and general difficulties in assessing response, as well as the varying potencies of the comparators. </p> <p>Compared with women receiving non‐platinum regimens: rates of grade 3 and 4 nausea/vomiting were probably higher among women receiving cisplatin‐ (RR 2.65, 95% CI 2.10 to 3.34; 1731 women; moderate‐quality evidence) but the effect from carboplatin‐containing regimens was less certain (RR 0.77, 95% CI 0.47 to 1.26; 1441 women; moderate‐quality evidence); rates of grade 3 and 4 anaemia were higher among women receiving cisplatin‐ (RR 3.72, 95% CI 2.36 to 5.88; 1644 women; high‐quality evidence) and carboplatin‐containing regimens (RR 1.72, 95% CI 1.10 to 2.70; 1441 women; high‐quality evidence); rates of grade 3 and 4 hair loss (RR 1.41, 95% CI 1.26 to 1.58; 1452 women; high‐quality evidence) and leukopenia (RR 1.38, 95% CI 1.21 to 1.57; 3176 women; moderate‐quality evidence) were higher among women receiving platinum‐containing regimens (regardless of platinum agent). </p> </section> <section id="CD003374-sec-0007"> <h3 class="title" id="CD003374-sec-0007">Authors' conclusions</h3> <p>In women with metastatic breast cancer who do not have triple‐negative disease, there is high‐quality evidence of little or no survival benefit and excess toxicity from platinum‐based regimens. There is preliminary low‐quality evidence of a moderate survival benefit from platinum‐based regimens for women with mTNBC. Further randomised trials of platinum‐based regimens in this subpopulation of women with metastatic breast cancer are required. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003374-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003374-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003374-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003374-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003374-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003374-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003374-abs-0004">日本語</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003374-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003374-abs-0003" lang="en"> <h3>Platinum‐containing regimens for metastatic breast cancer</h3> <p><b>What is the issue?</b> Metastatic breast cancer occurs when the cancer has spread to areas of the body beyond the breast and nearby lymph nodes. Although metastatic breast cancer is generally not curable, it is widely accepted that women with metastatic disease should receive some form of chemotherapy to help ease the severity of disease symptoms, while hopefully extending survival time. Chemotherapy containing platinum is known to be effective for treating a number of cancer types including lung, testicular, head and neck, bladder and ovarian cancers, but it also known to cause more adverse effects (such as nausea and vomiting, hair loss, anaemia, kidney damage and leukopenia (low white blood cells)) than other chemotherapy options. The two platinum agents most commonly used for treating metastatic breast cancer are carboplatin and cisplatin. </p> <p>The original version of this review (2004) concluded that chemotherapy containing platinum did not increase survival time for women treated for metastatic breast cancer. Since then, however, researchers have discovered that there are a variety of subtypes of breast cancer which may respond differently to different types of chemotherapy. One of these subtypes — triple‐negative breast cancer (TNBC) — makes up approximately 12 to 17% of breast cancers and is associated with shorter survival and higher likelihood that the cancer returns. Some researchers have speculated that chemotherapy containing platinum might be more effective in treating metastatic TNBC (mTNBC) than other chemotherapy options. </p> <p><b>Why does it matter?</b> There are at least two reasons why it is important to update the evidence on this topic. First, it is important to assess whether our 2004 conclusions — based on 12 early studies — are representative of the 24 studies who have now published or provided results through to 2015. Second, it is important to assess whether chemotherapy containing platinum increases survival for women with mTNBC more than other chemotherapy options. </p> <p><b>We asked</b> whether chemotherapy treatments containing a platinum agent are more or less effective for treating women with metastatic breast cancer than chemotherapy treatments not containing a platinum agent. We also asked the same question, but with a focus on women with mTNBC. </p> <p><b>We found</b> 24 studies involving 4418 women. The evidence is current to May 2015. Five of the 24 studies specifically assessed women with mTNBC while the other 19 studies assessed women with metastatic breast cancer in general (mainly women without mTNBC). This review found that, compared to chemotherapy without platinum, chemotherapy with platinum did not increase survival time by any important degree for women with metastatic breast cancer in general (mainly women without mTNBC). The quality of the evidence for this was considered to be high, meaning that we are confident about the results. For women with mTNBC, however, this review found that chemotherapy containing platinum may increase survival time over chemotherapy without platinum, but the quality of the evidence for this is low at this point in time (largely due to the small number of studies that have assessed mTNBC). This review also found that chemotherapy including platinum reduced the number of breast cancer recurrences compared to chemotherapy that did not contain platinum in women with mTNBC, however these findings also currently come from low‐quality evidence. There was no difference in the number of breast cancer recurrences for women receiving platinum or non‐platinum chemotherapy for metastatic breast cancer in general. Chemotherapy with platinum was more likely to shrink tumours compared to chemotherapy without platinum, but this result needs to be considered cautiously. </p> <p>Compared with women receiving chemotherapy without platinum, women receiving chemotherapy with platinum experienced higher rates of nausea/vomiting, anaemia, leukopenia and hair loss. </p> <p><b>This means</b> it is difficult to justify using chemotherapy containing platinum for the treatment of metastatic breast cancer that is not mTNBC, given that similarly effective but less toxic chemotherapy is commonly available. Chemotherapy containing platinum may provide a survival benefit to mTNBC participants of sufficient magnitude to justify its use, but the quality of the evidence for this is low at this point in time. Further studies are required before a more definitive conclusion can be made. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003374-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003374-sec-0090"></div> <h3 class="title" id="CD003374-sec-0091">Implications for practice</h3> <section id="CD003374-sec-0091"> <p>In view of the excess toxicity and limited survival benefits from platinum‐based regimens, it is difficult to justify their use over commonly‐available less toxic active agents as first‐line treatment for metastatic patients without mTNBC. On the other hand, this review update found preliminary low‐quality evidence of a moderate survival benefit for women with mTNBC. Consequently, although the evidence may be premature to recommend widespread use of platinum‐based regimens for mTNBC patients, some women and clinicians may consider platinum‐based regimens worth trying. While evidence from this review suggested that carboplatin was generally associated with less toxicity than cisplatin, it is not yet clear whether the possible benefits for women with mTNBC are related to the type of platinum agent. </p> </section> <h3 class="title" id="CD003374-sec-0092">Implications for research</h3> <section id="CD003374-sec-0092"> <p>It seems unlikely that the inclusion of additional randomised trials could alter our conclusion that platinum‐containing regimens offer little or no survival benefit for women with metastatic breast cancer that is not confirmed to be mTNBC. In contrast, however, our finding of a moderate survival benefit for women with mTNBC was based on low‐quality evidence from only three trials; hence, additional randomised trials are necessary to confirm this finding. It is also worth noting that <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> did not find an OS, PFS or OTRR advantage for women with mTNBC receiving carboplatin (vs docetaxel). However, in subgroup analysis restricted to 43 <a href="./references#CD003374-bbs2-0036" title="Triple negative trial: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER‐, PR‐ and HER2‐breast cancer. clinicaltrials.gov/show/NCT00532727 (accessed 12 April 2016). ">BRCA</a>1/2 positive participants, <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> found carboplatin was associated with significantly better OTRRs, perhaps suggesting a useful line of future research. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003374-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003374-sec-0029"></div> <div class="table" id="CD003374-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Platinum‐containing regimens for women with metastatic breast cancer unselected for triple‐negative disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Platinum compared to non‐platinum chemotherapy regimens for women with metastatic breast cancer unselected for triple‐negative disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> platinum<br/> <b>Comparison:</b> non‐platinum chemotherapy regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants (treatment‐ comparisons)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with non‐platinum chemotherapy regimens</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with platinum</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall survival ‐ trials of metastatic breast cancer participants unselected for TNBC </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 1.01<br/> (0.92 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2531 (16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: P = 0.09, I<sup>2</sup>=34% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1,000<br/> (289 to 340)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2‐year risk of death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>540 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>543 per 1,000<br/> (510 to 581)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression‐free survival/time to progression (randomised participants) ‐ trials of metastatic breast cancer participants unselected for TNBC </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of progression or death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.92<br/> (0.84 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1745 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: P = 0.08, I<sup>2</sup>=38% </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>737 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>707 per 1,000<br/> (674 to 740)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2‐year risk of progression or death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>891 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>869 per 1,000<br/> (844 to 893)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective tumour response rate (assessable participants) ‐ trials of metastatic breast cancer participants unselected for TNBC </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>493 per 1,000 <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>547 per 1,000<br/> (512 to 586) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11<br/> (1.04 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3252 (23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity: P = 0.0002, I<sup>2</sup>=58% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Estimated from the average of non‐platinum group Kaplan‐Meier probabilities from the three highest weighted non‐TNBC treatment‐comparisons for this outcome </p> <p><sup>2</sup> Estimated as 1000*(1‐S(t)<sup>HR</sup>) where S(t) is the estimated probability of survival for non‐platinum participants and HR is the pooled hazard ratio (<a href="./references#CD003374-bbs2-0048" title="DaviesHT . Interpreting measures of treatment effect. Hospital Medicine1998;59(6):499‐501. ">Davies 1998</a>) </p> <p><sup>3</sup> Quality of evidence for OS was not downgraded for blinding because this outcome is unlikely to be affected by non‐blinding. </p> <p><sup>4</sup> Downgraded quality of evidence one level for 'indirectness' because this outcome is a surrogate endpoint of questionable validity for assessing the more important outcome of OS in the context of metastatic breast cancer (<a href="./references#CD003374-bbs2-0045" title="BurzykowskiT , BuyseM , Piccart‐GebhartMJ , SledgeG , CarmichaelJ , LückHJ , et al. Evaluation of tumor response, disease control, progression‐free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology2008;26(12):1987‐92. ">Burzykowski 2008</a>) </p> <p><sup>5</sup> Estimated from all 23 non‐TNBC treatment‐comparisons in the review </p> <p><sup>6</sup> Downgraded quality of evidence one level for 'inconsistency' because there was substantial evidence of heterogeneity across studies (P &lt; 0.05) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003374-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Platinum‐containing regimens for women with metastatic triple‐negative breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Platinum compared to non‐platinum chemotherapy regimens for women with metastatic triple‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic triple‐negative breast cancer (mTNBC)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> platinum<br/> <b>Comparison:</b> non‐platinum chemotherapy regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants (treatment‐ comparisons)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with non‐platinum chemotherapy regimens</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with platinum</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall survival ‐ trials of mTNBC participants</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.75<br/> (0.57 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>391 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: P = 0.23, I<sup>2</sup> = 32% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>485 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1,000<br/> (315 to 485)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2‐year risk of death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>655 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1,000<br/> (455 to 655)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression‐free survival/time to progression (randomised participants) ‐ trials of mTNBC participants </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.59<br/> (0.49 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>391 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: P = 0.07, I<sup>2</sup> = 67% </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>894 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>733 per 1,000<br/> (667 to 801)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2‐year risk of death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>987 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>922 per 1,000<br/> (879 to 955)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective tumour response rate (assessable participants) ‐ trials of mTNBC participants</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>354 per 1,000<sup>7</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1,000<br/> (400 to 552) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.33<br/> (1.13 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>878 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>6,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity: P = 0.0010, I<sup>2</sup> = 78% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Estimated from the average of non‐platinum group Kaplan‐Meier probabilities from the three TNBC treatment‐comparisons contributing data for pooling on this outcome </p> <p><sup>2</sup> Estimated as 1000*(1‐S(t)<sup>HR</sup>) where S(t) is the estimated probability of survival for non‐platinum participants and HR is the pooled hazard ratio (<a href="./references#CD003374-bbs2-0048" title="DaviesHT . Interpreting measures of treatment effect. Hospital Medicine1998;59(6):499‐501. ">Davies 1998</a>) </p> <p><sup>3</sup> Downgraded quality of evidence one level for 'imprecision' because the confidence interval for the pooled estimate is wide and crosses or nearly crosses unity </p> <p><sup>4</sup> Downgraded quality of evidence one level for 'suspected publication bias' because <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> is a large study with 376 participants but has so far only reported median OS/PFS times. As a consequence, the study did not contribute to the pooled HR estimates for OS or PFS/TTP. The reported median OS/PFS times in <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> were similar between platinum and non‐platinum regimens. Hence, it seems likely that if HRs from <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> were able to be included in pooled HR estimates, these pooled estimates would be considerably closer to the null. </p> <p><sup>5</sup> Quality of evidence for OS was not downgraded for blinding because this outcome is unlikely to be affected by non‐blinding. </p> <p><sup>6</sup> Downgraded quality of evidence one level for 'indirectness' because this outcome is a surrogate endpoint of questionable validity for assessing the more important outcome of OS in the context of metastatic breast cancer (<a href="./references#CD003374-bbs2-0045" title="BurzykowskiT , BuyseM , Piccart‐GebhartMJ , SledgeG , CarmichaelJ , LückHJ , et al. Evaluation of tumor response, disease control, progression‐free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology2008;26(12):1987‐92. ">Burzykowski 2008</a>) </p> <p><sup>7</sup>Estimated from all five TNBC treatment‐comparisons in the review </p> <p><sup>8</sup> Downgraded quality of evidence one level for 'inconsistency' because there was substantial evidence of heterogeneity across studies (P &lt; 0.05) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003374-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Platinum‐containing regimens and toxicity profile</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Platinum compared to non‐platinum chemotherapy regimens for nausea/vomiting, anaemia, hair loss and leukopenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic breast cancer<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> platinum<br/> <b>Comparison:</b> non‐platinum chemotherapy regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants (treatment‐ comparisons)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with non‐platinum chemotherapy regimens</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with platinum</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Nausea/vomiting* grade 3 or 4 (safety population) by type of platinum agent in platinum regimen </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Carboplatin</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 0.77, 95% CI 0.47 to 1.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1441 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Test for carboplatin/cisplatin subgroup difference: P &lt; 0.0001</p> <p>Heterogeneity among carboplatin studies: P = 0.30, I<sup>2</sup> = 17% </p> <p>Heterogeneity among cisplatin studies: P = 0.010, I<sup>2</sup> = 32% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1,000<br/> (59 to 101) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Cisplatin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 2.65, 95% CI 2.10 to 3.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1747 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1,000<br/> (167 to 266) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Anaemia grade 3 or 4 (safety population) by type of platinum agent in platinum regimen</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Carboplatin</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 1.72, 95% CI 1.10 to 2.70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1441 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Test for carboplatin/cisplatin subgroup difference: P = 0.02</p> <p>Heterogeneity among carboplatin studies: P = 0.67, I<sup>2</sup> = 0% </p> <p>Heterogeneity among cisplatin studies: P = 0.50, I<sup>2</sup> = 0% </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1,000<br/> (36 to 89) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Cisplatin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 3.72, 95% CI 2.36 to 5.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1644 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕</p> <p>HIGH</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1,000<br/> (78 to 194) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hair loss grade 3 or 4 (safety population)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Carboplatin or cisplatin</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 1.41, 95% CI 1.26 to 1.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1452 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Test for carboplatin/cisplatin subgroup difference: P = 0.23</p> <p>Heterogeneity: P = 0.10, I<sup>2</sup> = 40% </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>264 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>372 per 1,000<br/> (333 to 417) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Leukopenia** grade 3 or 4 (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Carboplatin or cisplatin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 1.38, 95% CI 1.21 to 1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3176 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Test for carboplatin/cisplatin subgroup difference: P = 0.22</p> <p>Heterogeneity: P = 0.0002, I<sup>2</sup> = 60% </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>179 per 1,000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>247 per 1,000 (217 to 281)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Estimated from all treatment‐comparisons (cisplatin and carboplatin) contributing data for pooling for this outcome </p> <p><sup>2</sup> Downgraded quality of evidence one level for 'imprecision' because the confidence interval for the pooled estimate is wide and does not rule out 'no effect' </p> <p><sup>3</sup> Downgraded quality of evidence one level for 'inconsistency' because there was substantial evidence of heterogeneity across studies (P &lt; 0.05) </p> <p>*data on vomiting was included if data on nausea/vomiting was reported separately</p> <p>**data on neutropenia was included if data on leukopenia was not reported</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003374-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003374-sec-0030"></div> <section id="CD003374-sec-0031"> <h3 class="title" id="CD003374-sec-0031">Description of the condition</h3> <p>Breast cancer is both the most common type of cancer in women and the most common cause of cancer death in women (<a href="./references#CD003374-bbs2-0052" title="FerlayJ , SoerjomataramI , ErvikM , DikshitR , EserS , MathersC , et al. Cancer incidence and mortality worldwide. GLOBOCAN 2012 : IARC Cancerbase No. 11. globocan.iarc.fr/Default.aspx (accessed prior to 25 May 2017). ">Ferlay 2013</a>). In 2012, there was an estimated 1.67 million estimated new cases and approximately 522,000 deaths from breast cancer worldwide, with an age standardised death rate (ASR) of 12.9 per 100,000 (<a href="./references#CD003374-bbs2-0052" title="FerlayJ , SoerjomataramI , ErvikM , DikshitR , EserS , MathersC , et al. Cancer incidence and mortality worldwide. GLOBOCAN 2012 : IARC Cancerbase No. 11. globocan.iarc.fr/Default.aspx (accessed prior to 25 May 2017). ">Ferlay 2013</a>). ASRs of 25 or greater were recorded that same year in Fiji (28.4), Bahamas (26.3), Nigeria (25.9), Former Yugoslav Republic (FYR) Macedonia (25.5) and Pakistan (25.2) (<a href="./references#CD003374-bbs2-0052" title="FerlayJ , SoerjomataramI , ErvikM , DikshitR , EserS , MathersC , et al. Cancer incidence and mortality worldwide. GLOBOCAN 2012 : IARC Cancerbase No. 11. globocan.iarc.fr/Default.aspx (accessed prior to 25 May 2017). ">Ferlay 2013</a>). </p> <p>The stage of breast cancer at the time of diagnosis is an important indicator of prognosis. Once breast cancer becomes metastatic, it is not generally considered curable and most women with metastatic disease do not survive beyond five years from the time of their metastatic diagnosis (<a href="./references#CD003374-bbs2-0047" title="ClementsMS , RoderDM , YuXQ , EggerS , O'ConnellDL . Estimating prevalence of distant metastatic breast cancer: a means of filling a data gap. Cancer Causes &amp; Control2012;23(10):1625‐34. ">Clements 2012</a>). Another important predictor of prognosis is the biological subtype of breast cancer. One of these subtypes — triple‐negative breast cancer (TNBC) — is characterised by a lack of expression of oestrogen and progesterone receptors (ER and PgR) and human epidermal receptor 2 (HER2). TNBC comprises approximately 12 to 17% of breast cancers and is associated with shorter survival and higher likelihood of recurrence (<a href="./references#CD003374-bbs2-0053" title="FoulkesWD , SmithIE , Reis‐FilhoJS . Triple‐negative breast cancer. NEJM2010;363(20):1938‐48. ">Foulkes 2010</a>). The median survival time for women diagnosed with metastatic TNBC (mTNBC) is about one year from their metastatic diagnosis (<a href="./references#CD003374-bbs2-0060" title="KassamF , EnrightK , DentR , DranitsarisG , MyersJ , FlynnC , et al. Survival outcomes for patients with metastatic triple‐negative breast cancer: implications for clinical practice and trial design. Clinical Breast Cancer2009;9(1):29‐33. ">Kassam 2009</a>). </p> <p>Although there is no evidence from randomised trials comparing chemotherapy with observation (no chemotherapy) in women with metastatic breast cancer, it is widely accepted that women with metastatic disease should receive some form of systemic therapy at some time during the course of their metastatic disease. Chemotherapy is considered by many to be the appropriate first treatment option for women with multiple sites of recurrence or where visceral disease is not easily treated by local modalities (<a href="./references#CD003374-bbs2-0057" title="HayesDF , HendersonIC , ShapiroCL . Treatment of metastatic breast cancer: present and future prospects. Seminars in Oncology1995;22(Suppl 5):5‐21. ">Hayes 1995</a>; <a href="./references#CD003374-bbs2-0044" title="BeslijaS , BonneterreJ , BursteinHJ , CocquytV , GnantM , HeinemannV , et al. Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology2009;20(11):1771‐85. ">Beslija 2009</a>). Chemotherapy is also considered to be useful in women whose cancer is hormone refractory or is expected to be hormone resistant (<a href="./references#CD003374-bbs2-0059" title="HortobagyiGN , Piccart‐GebhartMJ . Current management of advanced breast cancer. Seminars in Oncology1996;23(Suppl 11):1‐5. ">Hortobagyi 1996</a>). </p> </section> <section id="CD003374-sec-0032"> <h3 class="title" id="CD003374-sec-0032">Description of the intervention</h3> <p>Platinum compound, an alkylating agent, has been known to be active in metastatic breast cancer since clinical trials in the 1970s. However, it is more toxic and difficult to administer than other chemotherapy agents. The three most widely used platinum agents for treating breast cancer are cisplatin, carboplatin (both divalent complexes) and oxaliplatin (a tetravalent complex) (<a href="./references#CD003374-bbs2-0067" title="SikovWM . Assessing the role of platinum agents in aggressive breast cancers. Current Oncology Reports2015;17(2):1‐10. ">Sikov 2015</a>). Cisplatin and carboplatin have demonstrated benefits in treating a number of cancer types including lung, testicular, head and neck, bladder and ovarian cancers. Oxaliplatin is often used to treat cisplatin‐ and carboplatin‐resistant tumours because it is commonly believed that cross‐resistance between oxaliplatin and cisplatin or carboplatin is incomplete (<a href="./references#CD003374-bbs2-0061" title="ManiS , GrahamMA , BregmanDB , IvyP , ChaneySG . Oxaliplatin: a review of evolving concepts. Cancer Investigation2002;20(2):246‐63. ">Mani 2002</a>). More recent evidence suggests that the benefits of oxaliplatin may be due to its low toxicity and ability to be combined with other drugs rather than incomplete cross‐resistance with other platinum agents (<a href="./references#CD003374-bbs2-0068" title="StordalB , PavlakisN , DaveyR . Oxaliplatin for the treatment of cisplatin‐resistant cancer: a systematic review. Cancer Treatment Reviews2007;33(4):347‐57. ">Stordal 2007</a>). </p> <p>The use of oxaliplatin for treating breast cancers is much less common than the use of cisplatin or carboplatin, both in normal clinical practice and as an intervention in clinical trials (<a href="./references#CD003374-bbs2-0067" title="SikovWM . Assessing the role of platinum agents in aggressive breast cancers. Current Oncology Reports2015;17(2):1‐10. ">Sikov 2015</a>). Cisplatin and carboplatin have been used and studied extensively as first‐line metastatic therapy in combination with other older pharmacological agents including 5‐fluorouracil and etoposide, and more recently with doxorubicin, epirubicin, vinorelbine, paclitaxel, docetaxel, cyclophosphamide, methotrexate and gemcitabine. The potential benefits of cisplatin or carboplatin as monotherapy for metastatic breast cancer, rather than as combination therapy, are rarely studied in clinical trials. </p> <p>Although platinum agents have been shown to be efficacious in the treatment of a number of cancer types, their use is often associated with a variety of side effects. The known side effects of platinum agents include nausea, vomiting, myelosuppression (thrombocytopenia, leukopenia, neutropenia and anaemia), peripheral neuropathy (symptoms include tingling in fingers and toes), nephrotoxicity, ototoxicities (hearing loss and tinnitus), hypomagnesaemia and anaphylaxis. Carboplatin is reported to be more tolerable than cisplatin with less nausea and vomiting, nephrotoxicity, ototoxicity and neurotoxicity, but worse myelosuppression, especially thrombocytopenia (<a href="./references#CD003374-bbs2-0067" title="SikovWM . Assessing the role of platinum agents in aggressive breast cancers. Current Oncology Reports2015;17(2):1‐10. ">Sikov 2015</a>). </p> </section> <section id="CD003374-sec-0033"> <h3 class="title" id="CD003374-sec-0033">How the intervention might work</h3> <p>The exact mechanism of action of platinum agents is not known but deoxyribonucleic acid (DNA) adducts are formed (<a href="./references#CD003374-bbs2-0067" title="SikovWM . Assessing the role of platinum agents in aggressive breast cancers. Current Oncology Reports2015;17(2):1‐10. ">Sikov 2015</a>). These complexes are believed to inhibit DNA synthesis, replication and transcription by forming interstrand and intrastrand cross‐linking of DNA molecules. Interstrand cross‐links that remain intact can produce cell death, and it is this cytotoxic effect, when successful, that forms the mechanistic basis of action for cancer cell death by platinum agents (<a href="./references#CD003374-bbs2-0062" title="NollDM , MasonTM , MillerPS . Formation and repair of interstrand cross‐links in DNA. Chemical Reviews2006;106(2):277‐301. ">Noll 2006</a>). For TNBC, it has been additionally hypothesised that a dysfunctional <a href="./references#CD003374-bbs2-0036" title="Triple negative trial: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER‐, PR‐ and HER2‐breast cancer. clinicaltrials.gov/show/NCT00532727 (accessed 12 April 2016). ">BRCA</a>1 pathway in some TNBCs may make them more sensitive to platinum agents that selectively target cells deficient in homologous recombination DNA repair (<a href="./references#CD003374-bbs2-0053" title="FoulkesWD , SmithIE , Reis‐FilhoJS . Triple‐negative breast cancer. NEJM2010;363(20):1938‐48. ">Foulkes 2010</a>). </p> </section> <section id="CD003374-sec-0034"> <h3 class="title" id="CD003374-sec-0034">Why it is important to do this review</h3> <p>There are a number of reasons for updating this review. First, this review was originally published in 2004 (<a href="./references#CD003374-bbs2-0046" title="CarrickS , GhersiD , WilckenN , SimesJ . Platinum containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD003374.pub3] ">Carrick 2004</a>) and was based on 12 studies (13 treatment‐comparisons) identified from a May 2003 search of the literature. Although there have since been some updates to this review containing minor amendments, no new searches for relevant studies have been conducted since 2003. In the current review update, the number of included studies has increased from 12 in the original version of this review to 24 (28 treatment‐comparisons). This allows effects to be estimated with greater precision than before and provides an opportunity to conduct new subgroup analyses corresponding to emerging evidence and new hypotheses. Second, all 12 studies included in the original version of this review were conducted prior to the 'intrinsic subtype' era and thus did not specifically focus on TNBC (a term first mentioned in the medical literature in October 2006) (<a href="./references#CD003374-bbs2-0053" title="FoulkesWD , SmithIE , Reis‐FilhoJS . Triple‐negative breast cancer. NEJM2010;363(20):1938‐48. ">Foulkes 2010</a>). Since 2009, however, five randomised control trials have published data specifically on the effects of platinum‐based regimens on survival, progression or tumour response in mTNBC participants; the inclusion of these five trials in this review update represents the first meta‐analysis of such trials. Third, some interest remains in the use of platinum agents for the treatment of women with metastatic breast cancer in general (i.e. unselected for intrinsic subtypes such as mTNBC) (<a href="./references#CD003374-bbs2-0066" title="ShamseddineAI , FarhatFS . Platinum‐based compounds for the treatment of metastatic breast cancer. Chemotherapy2012;57(6):468‐87. ">Shamseddine 2012</a>). This is notwithstanding the primary conclusion contained in the original version of this review that "...in view of the significant excess toxicity, lack of progression or survival benefit and the availability of less toxic active agents it is difficult to justify the use of platinum‐containing regimens, particularly as first‐line treatment for women with metastatic breast cancer in routine clinical practice." </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003374-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003374-sec-0035"></div> <p>To identify and review the evidence from randomised trials comparing platinum‐containing chemotherapy regimens with regimens not containing platinum in the management of women with metastatic breast cancer. </p> <p>Additional objectives of this review were to investigate whether or not women in selected subgroups of studies benefited more or less from platinum‐based chemotherapy. Some subgroup analyses included in this review update were conducted in the original version of this review, while others have been added in response to new hypotheses and the availability of new subgroups. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003374-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003374-sec-0036"></div> <section id="CD003374-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003374-sec-0038"> <h4 class="title">Types of studies</h4> <p>Properly randomised controlled clinical trials (i.e. where the trial report asserts that the trial was randomised and there was no evidence to suggest otherwise). </p> </section> <section id="CD003374-sec-0039"> <h4 class="title">Types of participants</h4> <p>Women with advanced (metastatic) breast cancer, either newly diagnosed or recurrent. Treatment‐comparisons that included both women with metastatic disease and women with loco‐regionally recurrent disease only were eligible for inclusion if it was possible to distinguish between the two groups (i.e. data were reported separately) or if women with isolated locoregional recurrence were less than 20% of the total group. There were no age restrictions.<br/> <br/> In the protocol for this review, it was proposed that treatment‐comparisons would be included if the women randomised to receive chemotherapy, were to receive it as first‐line treatment (i.e. no previous chemotherapy given except as adjuvant therapy). As few treatment‐comparisons assessing first‐line treatment were identified for inclusion in the original version of this review, those meeting the remaining eligibility criteria but which involved participants who were not first‐line naive were included. This modification of the inclusion criteria was maintained for this review update, with subgroup analysis by treatment being performed (treatment‐comparisons with first‐line therapy for &gt; 80% of participants vs other treatment lines). </p> </section> <section id="CD003374-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Interventions were any chemotherapy regimen containing a platinum agent (see <a href="#CD003374-tbl-0004">Table 1</a> and <a href="#CD003374-tbl-0005">Table 2</a>). Comparators were any chemotherapy regimen without a platinum agent. Endocrine therapy may also have been given to participants if it was planned to be given to both treatment groups.<br/> <br/> Studies may or may not have specified recommended treatment upon disease progression or initial treatment failure or both. This recommended treatment may have included cross‐over to the alternative treatment arm of the treatment‐comparison. </p> <div class="table" id="CD003374-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Platinum agents</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Generic name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other names</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, Nealorin, Novoplatinum, Paraplat, Paraplatin AQ, Paraplatin, Paraplatine, Platinwas, Ribocarbo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abiplatin, Blastolem, Briplatin,CACP, CDDP, cis‐DDP, cis‐diamminedichloridoplatinum, cis‐diamminedichloro platinum (II), cis‐diamminedichloroplatinum, Cis‐dichloroammine Platinum (II), Cismaplat, Cisplatina, cis‐platinous diamine dichloride, cis‐platinum II diamine dichloride, cis‐platinum II, cis‐platinum, Cisplatyl, Citoplatino, Citosin, CPDD, Cysplatyna, DDP, DDP, Lederplatin, Metaplatin, Neoplatin, PDD, Peyrone's Chloride, Peyrone's Salt, Placis, Platamine, Platiblastin, Platiblastin‐S, Platinex, Platinol‐ AQ, Platinol, Platinol‐AQ VHA Plus, Platinol‐AQ, Platinoxan, platinum diamminodichloride, Platiran, Platistin, Platosin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxaliplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ai Heng, Aiheng, diaminocyclohexane oxalatoplatinum, oxalatoplatin, oxalatoplatinum, oxaliplatine, Eloxatin, Dacotin, Dacplat, Eloxatine, 1‐OHP, L‐OHP, oxaliplatin medac </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003374-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Chemotherapeutic Agents (adapted from Table 1.1 in The Chemotherapy Source Book)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of Agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Action</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Includes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agents that damage the DNA template</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: nitrogen mustards</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cyclophosphamide, melphalan, ifosfamide, chlorambucil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: nitrosureas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>carmustine (BCNU), lomustine (CCNU)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: other agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>thiotepa, mitomycin C</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by platinum coordination cross‐linking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cisplatin, carboplatin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>doxorubicin, daunorubicin, mitoxantrone, idarubicin, epirubicin, amsacrine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>podophyllotoxins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>etoposide, teniposide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by intercalation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dactinomycin, mithramycin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by uncertain mechanisms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bleomycin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spindle poisons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vinca alkaloids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vincristine, vinblastine, vendesine, vinorelbine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>taxanes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>taxol, taxotere</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antimetabolites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>thymidylate synthase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐fluorouracil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydrofolate reductase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>methotrexate</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD003374-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD003374-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003374-list-0001"> <li> <p>Overall survival (OS)</p> </li> <li> <p>Progression‐free survival/time to progression (PFS/TTP)</p> </li> </ul> </p> </section> <section id="CD003374-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003374-list-0002"> <li> <p>Time to treatment failure (TTF)</p> </li> <li> <p>Objective tumour response rate (OTRR)</p> </li> <li> <p>Toxicity rates (multiple condition‐specific outcomes)</p> </li> <li> <p>Quality of life measures (multiple outcomes)</p> </li> </ul> </p> <p>The definitions of some outcomes varied slightly across studies included in this review. Outcomes were commonly defined as: </p> <p> <ol id="CD003374-list-0003"> <li> <p>Overall survival (OS): time elapsed between randomisation (or study enrolment or treatment initiation) to date of death from any cause. </p> </li> <li> <p>Progression‐free survival (PFS): time elapsed between randomisation (or study enrolment or treatment initiation) and event, with event defined as disease progression or death from any cause. </p> </li> <li> <p>Time to progression (TTP): time elapsed between randomisation (or study enrolment or treatment initiation) and event, with event defined as disease progression (which sometimes included cause‐specific death from the study disease). </p> </li> <li> <p>Time to treatment failure (TTF): time elapsed between randomisation (or study enrolment or treatment initiation) to treatment discontinuation for any reason, including disease progression, treatment toxicity, participant preference, or death. </p> </li> <li> <p>Objective tumour response rate (OTRR): the proportion of participants who experienced a complete or partial tumour response (versus stable disease or no response). </p> </li> <li> <p>Toxicity rates (multiple condition‐specific outcomes): the proportions of participants who experienced a grade 3 or 4 adverse event of nausea and vomiting, nephrotoxicity, anaemia, hair loss and leukopenia based on WHO criteria or individual protocol‐based definitions. We also investigated treatment‐related death which, for the purpose of this review, was defined as death due to the toxicity of the drug and not to disease progression. If an individual trial did not include their definition of a treatment‐related death but used the terms 'toxic death' or 'lethal toxicity', then these deaths were still included in the pooled analysis of treatment related deaths. </p> </li> <li> <p>Quality of life measures (QoL) (multiple outcomes): various validated instruments for measuring various quality of life domains. </p> </li> </ol> </p> <p>For the purposes of this review, PFS and TTP were analysed as the same outcome (referred to as PFS/TTP), with preference given to PFS for studies reporting both PFS and TTP extractable data. </p> </section> </section> </section> <section id="CD003374-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003374-sec-0045"> <h4 class="title">Electronic searches</h4> <p>For this update of the review, we searched the following databases and registries on the 28 May 2015. </p> <p>(a) The Cochrane Breast Cancer Specialised Register maintained by the Cochrane Breast Cancer Group (searched 1 June 2015). Details of the search strategies used by the Cochrane Breast Cancer Group for the identification of studies and the procedure used to code references are outlined in their module (<a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html" target="_blank">www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html</a>). Trials coded with the key words 'advanced', 'Cisplatin', 'cisplatinum', 'carboplatin', 'carboplatinum', 'platin', 'platinum', 'platinum diamminodichloride', 'cis‐diamminedichloroplatinum', 'cis‐dichlorodiammineplatinum', 'biocisplatinum', 'dichlorodiammineplatinum', 'nsc‐119875', 'platidiam', 'platino', 'Platinol', 'cis‐diamminedichloroplatinum', 'cis‐platinum', 'cis‐diammine (cyclobutanedicarboxylato) platinum', 'cbdca', 'jm‐8', 'nsc‐241240', 'paraplatin' were extracted for consideration.<br/> (b) Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 4) in the Cochrane Library (searched 28 May 2015). See <a href="./appendices#CD003374-sec-0096">Appendix 1</a>.<br/> (c) MEDLINE (via OvidSP; July 2008 to 28 May 2015). Searches were conducted from 2008 due to the Cochrane Breast Cancer Group's Specialised Register being out‐of‐date for an interim period. See <a href="./appendices#CD003374-sec-0097">Appendix 2</a>.<br/> (d) Embase (Via Embase.com; July 2008 to 28 May 2015). Searches were conducted from 2008 due to the Cochrane Breast Cancer Group's Specialised Register being out‐of‐date for an interim period. See <a href="./appendices#CD003374-sec-0098">Appendix 3</a>.<br/> (e) The WHO International Clinical Trials Registry Platform (ICTRP) search portal (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">http://apps.who.int/trialsearch/Default.aspx</a>) for all prospectively registered and ongoing trials. See <a href="./appendices#CD003374-sec-0099">Appendix 4</a>.<br/> (f) ClinicalTrials.gov (<a href="http://clinicaltrials.gov/ct2/home" target="_blank">http://clinicaltrials.gov/ct2/home</a>). See <a href="./appendices#CD003374-sec-0100">Appendix 5</a>. </p> <p>No restrictions were applied based on language.</p> </section> <section id="CD003374-sec-0046"> <h4 class="title">Searching other resources</h4> <p>In addition, we searched the reference lists of other, related literature reviews.</p> </section> </section> <section id="CD003374-sec-0047"> <h3 class="title" id="CD003374-sec-0047">Data collection and analysis</h3> <section id="CD003374-sec-0048"> <h4 class="title">Selection of studies</h4> <p>In the original version of this review and in this review update, two reviewers applied the selection criteria (including the quality of randomisation) to each reference identified by the search strategy while masked to the study results. Any discrepancies regarding eligibility or quality were resolved by consensus or adjudication from a third reviewer. Studies that may appear to have met the eligibility criteria, but which were deemed ineligible are listed in the <a href="./references#CD003374-sec-0113" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD003374-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>In the original version of this review and in this review update, data on the relevant outcomes were extracted by at least two reviewers, with discrepancies resolved by consensus or adjudication from another reviewer. Data were also extracted on information relating to outcome definitions, study accrual, randomisation methods, baseline characteristics of participants (e.g. age, first‐line/second‐line treatment, prior anthracyclines/anthracycline‐naïve), chemotherapy regimens (number of cycles and duration), follow‐up time and analytical methods used. Where available, multiple publications on the same study were obtained and the most complete report was assigned as the primary reference. In instances where a more recent publication was used in this review update for a study that was included in the original version of this review, the year of the reference ID was also updated. Data were entered into the Cochrane Review Manager 5.3 (<a href="./references#CD003374-bbs2-0065" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 5.3</a>) software, and <a href="./references#CD003374-bbs2-0065" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 5.3</a> was used for most statistical analyses. </p> </section> <section id="CD003374-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>In this review update, potential sources of bias for all included studies (including those in the original version of this review) were assessed using Cochrane's 'Risk of bias' assessment tool (<a href="./references#CD003374-bbs2-0058" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Risk of bias for each treatment‐comparison was evaluated independently by at least two reviewers and discrepancies were resolved by consensus or adjudication from an additional reviewer. Clarification from authors was sought if the published data provided inadequate information for the review. The 'risk of bias' domains that were assessed were 'random sequence generation', 'allocation concealment', 'blinding of participants and personnel', 'blinding of outcome assessment', 'incomplete outcome data', 'selective reporting' and 'other bias'. For each included study, ratings of 'high', 'low', or 'unclear' risk of bias were assigned for each risk of bias domain following criteria outlined in the 'Risk of bias' assessment tool (<a href="./references#CD003374-bbs2-0058" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>Open‐label studies are common in phase III oncology trials because it is often difficult to conceal treatments from participants, care‐providers and outcome assessors (due to differences in toxicities and treatment schedules of various treatments, for example). However, because a lack of blinding can affect risk of bias in different ways for different outcomes, we assessed 'blinding of outcome assessment' by dividing outcomes into two outcome classes: 1) OS and 2) outcomes other than OS and quality of life. This division was made because, unlike other outcomes, assessment of OS is unlikely to be affected by non‐blinding. </p> <p>We also divided the 'incomplete outcome data' risk of bias domain into two outcome classes: 1) time‐to‐event outcomes and 2) binary (i.e. dichotomous) outcomes. For time‐to‐event outcomes, risk of bias was deemed low, unclear, and high risk if time‐to‐event analysis was intention‐to‐treat (ITT), modified intention‐to‐treat (mITT) or per‐protocol, respectively. For the binary outcomes (OTRRs and toxicity rates), risk of bias was deemed low, unclear, and high risk if the highest percentage of randomised participants excluded from effect estimation was less than 10%, between 10% and 15%, or more than 15%, respectively. </p> <p>For 'risk of bias' domains that were divided into outcome classes, assessments were made for all studies known to be measuring the outcomes, regardless of results being reported in sufficient detail to be included in meta‐analysis or reported at all (e.g. a study might specify OS as an outcome in the study protocol but not report any results). </p> </section> <section id="CD003374-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>OS, PFS/TTP and TTF were analysed as time‐to‐event outcomes, for which the hazard ratio (HR) is the most appropriate measure of treatment effect. If reported, the HR and associated variance were extracted directly from the trial publication(s), and these were used to calculate observed (O) minus expected (E) numbers of events and logrank variance (V) for each treatment‐comparison using the methods described by <a href="./references#CD003374-bbs2-0069" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8(1):1. ">Tierney 2007</a> or <a href="./references#CD003374-bbs2-0063" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815‐34. ">Parmar 1998</a>. If not reported, O ‐ E and V were obtained indirectly from other available summary statistics or from data extracted from published Kaplan‐Meier curves using the methods described by <a href="./references#CD003374-bbs2-0069" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8(1):1. ">Tierney 2007</a> or <a href="./references#CD003374-bbs2-0063" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815‐34. ">Parmar 1998</a>. For studies that did not report the relevant effect estimates and required curve extraction, the numbers at risk were based on reported minimum and maximum follow‐up times. If these were not reported, minimum follow‐up was estimated as the time taken to complete treatment, and maximum follow‐up was estimated using the last event reported in the relevant time‐to‐event curve. These follow‐up estimates were recorded in the <a href="./references#CD003374-sec-0112" title="">Characteristics of included studies</a> table under 'Notes'. For the purposes of data extraction, preference was given to time‐to‐event effect estimates derived from ITT analysis, followed by mITT analysis, then per‐protocol analysis. </p> <p>Pooled HRs and 95% confidence intervals (CIs) were obtained from the O ‐ E and V statistics for each treatment‐comparison using the fixed‐effect model (<a href="./references#CD003374-bbs2-0070" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases.1985;5:335‐71. ">Yusuf 1985</a>). The pooled HR represented the instantaneous risk of an event (such as death, disease progression or treatment failure) for women receiving platinum divided by the corresponding risk for those not receiving platinum. HRs less than 1.00 favoured the platinum‐containing regimens and values greater than 1.00 favoured non‐platinum regimens. </p> <p>Toxicity rates and OTRRs were analysed as proportions using the risk ratio (RR) as the measure of treatment effect. OTRRs were most often calculated by trialists using only participants that were assessable for tumour response. These 'assessable participants' were generally defined as participants whose tumour response could be assessed according to prespecified criteria such as RECIST (<a href="./references#CD003374-bbs2-0051" title="EisenhauerE , TherasseP , BogaertsJ , SchwartzLH , SargentD , FordR , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer2009;45(2):228‐47. ">Eisenhauer 2009</a>), but this definition was sometimes extended to additionally exclude participants who had not received a specified minimum dose of chemotherapy. In this review update and in the original version of this review, we calculated OTRRs using the numbers of assessable participants in the OTRR denominators, but we also separately calculated OTRRs using the numbers of randomised participants in the denominators. In this review update, however, only the results from the assessable participants analyses were reported as there was almost no difference between the results obtained using assessable and randomised participant denominators (the latter are available on request). Toxicity rates were most often calculated by trialists using a 'safety population' of participants who received a specified minimum dose of chemotherapy. We calculated toxicity rates for each study using the population used by that study. </p> <p>Pooled RRs and 95% confidence intervals were obtained through Mantel‐Haenszel fixed‐effect analysis. The pooled RR represented the cumulative risk of an event for participants receiving platinum divided by the corresponding risk for those not receiving platinum. RRs greater than 1.00 favoured platinum‐containing regimens and values less than 1.00 favoured non‐platinum regimens. </p> <p>Quality of life was generally reported as a continuous outcome. Hence, if sufficient quality of life data become available for meta‐analysis in future review updates, the effect measure would most likely be the mean difference (MD) or standardised mean difference (SMD), depending on whether the same or different validated questionnaires (respectively) were employed. </p> </section> <section id="CD003374-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>Treatment‐comparisons were the unit of analysis in this review and corresponded to pairwise comparisons of platinum and non‐platinum regimens. Individual studies assessing more than one platinum‐based regimen or more than one non‐platinum regimen (or both) contributed more than one treatment‐comparison to the review. Consequently, there were more treatment‐comparisons in this review than there were studies. </p> <p>Two studies each contained two non‐platinum regimen (control) groups for comparison against a single platinum‐based regimen (intervention) group. This was taken into account when treatment effect statistics were calculated by splitting each study into two treatment‐comparisons (<a href="./references#CD003374-bbs2-0023" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 A</a>, <a href="./references#CD003374-bbs2-0024" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 B</a> and <a href="./references#CD003374-bbs2-0015" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 A</a>, <a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a>) and halving the number of participants in their intervention groups (for odd numbered group sizes, the additional participant was arbitrarily distributed to the treatment‐comparison with label ending with 'A'). Another study contained two platinum‐based regimen (intervention) groups for comparison against a single non‐platinum (control) group. This study was split into two treatment‐comparisons (<a href="./references#CD003374-bbs2-0027" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 A</a>, <a href="./references#CD003374-bbs2-0028" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 B</a>) with treatment effect statistics calculated by halving the number of participants in the control group (with additional participants again arbitrarily distributed to treatment‐comparisons with label ending with 'A'). One other study was a four‐armed trial and was also reported as two separate treatment‐comparisons (<a href="./references#CD003374-bbs2-0002" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 A</a>, <a href="./references#CD003374-bbs2-0003" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 B</a>). For these two treatment‐comparisons, no adjustments to participant numbers were required as their control and intervention groups were unique to each comparison. These methods for correcting for multiple intervention and/or control groups were suggested in the Cochrane Handbook (<a href="./references#CD003374-bbs2-0058" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD003374-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>Attempts were made to contact a number of trial investigators for additional information. Three trialists (Cocconi, Costanza and Fountzilas) provided additional time‐to‐event data which allowed HRs to be extracted. </p> </section> <section id="CD003374-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity between trial results was assessed using the Chi<sup>2</sup> test statistic and the I<sup>2</sup> statistic. The Chi<sup>2</sup> test statistic assesses the amount of variation in a set of trials. Small P values for the Chi<sup>2</sup> test statistic suggest that there is more heterogeneity present than would be expected by chance. Chi<sup>2</sup> is not a particularly sensitive test: a cut‐off of P value less than 0.10 is often used to indicate significance, but lack of statistical significance does not mean there is no heterogeneity. I<sup>2</sup> is the proportion of variation that is due to heterogeneity rather than chance. In conjunction with the Chi<sup>2</sup> test, we used the I<sup>2</sup> statistic to assess heterogeneity using the rule of thumb guide outlined in the Cochrane Handbook (<a href="./references#CD003374-bbs2-0058" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) (i.e. I<sup>2</sup> between 0% to 40% might not be important; between 30% to 60% may represent moderate heterogeneity; between 50% to 90% may represent substantial heterogeneity; and between 75% to 100% considerable heterogeneity). </p> </section> <section id="CD003374-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>In addition to assessing each treatment‐comparison individually for 'selective reporting' using the Cochrane Collaboration's 'Risk of bias' assessment tool (see <a href="#CD003374-sec-0050">Assessment of risk of bias in included studies</a> above), publication bias and/or small‐study effects were assessed for the outcomes OS, PFS/TTP and OTRR by visual inspection of funnel plot asymmetry. Egger's statistical test was used to formally assess the degree of asymmetry (<a href="./references#CD003374-bbs2-0050" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>). </p> </section> <section id="CD003374-sec-0056"> <h4 class="title">Data synthesis</h4> <p>For time‐to‐event outcomes, <a href="./references#CD003374-bbs2-0065" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 5.3</a> was used to estimate pooled HRs and 95% CIs using fixed‐effect models of the derived or reported observed (O) and expected (E) number of events and the variance of the log‐rank statistic (V) for each trial. For binary outcomes, <a href="./references#CD003374-bbs2-0065" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 5.3</a> was used to estimate pooled RRs and 95% CIs using the fixed‐effect Mantel‐Haenszel method. </p> <p>The standard GRADE system (<a href="./references#CD003374-bbs2-0056" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. the GRADE Working Group. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. ">Guyatt 2011</a>) was to use to rate the quality of evidence relating to the estimated treatment effects on OS, PFS/TTP, OTRR, nausea/vomiting, anaemia, hair loss and leukopenia. GRADE criteria for assessing quality of evidence include 'study design', 'risk of bias', 'inconsistency', 'indirectness', 'imprecision', 'suspected publication bias' and 'other considerations'. Assessments of these criteria and corresponding justifications are provided in three 'Summary of findings' tables largely created using GRADEproGDT (<a href="./references#CD003374-bbs2-0054" title="GRADEproGDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from www.gradepro.org. ">GradeproGDT</a>). GRADE assessments were performed separately for selected subgroups related to effect estimate heterogeneity (or 'inconsistency' as labelled in the GRADE assessment criteria). </p> </section> <section id="CD003374-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were performed to determine whether the results differed by:</p> <p> <ol id="CD003374-list-0004"> <li> <p>mTNBC status: (a) mTNBC participants, (b) participants unselected for mTNBC;</p> </li> <li> <p>type of regimen comparison: (a) regimen A + platinum vs regimen A, (b) regimen A + platinum vs regimen B, (c) single agent platinum vs regimen C; (note that we allowed "regimen A" to differ in dosage by small amounts between intervention and control arms) </p> </li> <li> <p>type of platinum agent in platinum arm: (a) cisplatin, (b) carboplatin, (c) oxaliplatin;</p> </li> <li> <p>first‐line therapy: (a) first‐line therapy for &gt; 80% of participants, (b) second‐ or third‐line therapy for ≥ 20% of participants; </p> </li> <li> <p>anthracycline in regimens: (a) no anthracycline in platinum or non‐platinum regimens, (b) platinum + anthracycline vs non‐platinum + anthracycline regimen, (c) platinum + anthracycline vs non‐platinum + non‐anthracycline regimens; </p> </li> <li> <p>taxane in regimens: (a) no taxane in platinum or non‐platinum regimens, (b) platinum + taxane vs non‐platinum + taxane regimens, (c) platinum + non‐taxane vs non‐platinum + taxane regimens; </p> </li> <li> <p>trastuzumab in regimens: (a) no trastuzumab in platinum or non‐platinum regimens, (b) platinum + trastuzumab vs non‐platinum + trastuzumab regimens </p> </li> </ol> </p> <p>Possible subgroup differences were assessed using Chi<sup>2</sup> tests. </p> <p>Of the above seven subgroup analyses:</p> <p> <ul id="CD003374-list-0005"> <li> <p>Subgroup analysis 2 was the only 'a priori' subgroup analysis pre‐specified in the review protocol; all other subgroup analyses were 'post hoc'. </p> </li> <li> <p>Subgroup analyses 2, 4, 5 and 6 were conducted in the original review, although additional subgroups have been added for some of these analyses (eg. the conjugate subgroup 'second‐ or third‐line therapy for ≥ 20% of participants' has been added to the 'first‐line therapy' analysis). </p> </li> <li> <p>In order to reduce the number of forest plots in this review update, toxicity rates were only assessed overall and by subgroup analysis 3 (as 'type of platinum agent' is known to be related to toxicity). Analyses of toxicity rates by other subgroups are available on request. </p> </li> </ul> </p> <p>In this review update, the subgroupings of a few studies have been corrected from the original version of the review. Furthermore, the subgroup analysis 'first‐line therapy' was incorrectly labelled '100% firstline trials' in the original version of the review and the actual cut‐off that was applied was first‐line therapy for &gt; 80% of participants. </p> </section> <section id="CD003374-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were performed to assess whether apparent inconsistencies in results relating to OS, PFS/TTP and OTRR were more likely to be due to differences in the underlying nature of these outcomes, or an artefact of the different treatment‐comparisons available for the meta‐analysis of each outcome. First, the pooled effect estimate for OTRR was recalculated restricting the meta‐analysis to the 19 treatment‐comparisons with extractable data on OS. Second, the pooled effect estimates for PFS/TTP and OS were recalculated restricting both meta‐analyses to the 12 treatment‐comparisons with extractable data on both OS and PFS/TTP. </p> <p>In additional sensitivity analyses, PFS/TTP estimates were stratified according to whether the outcome was PFS or TTP. For these analyses, estimates were classified as PFS if the event of interest was defined as disease progression or death from any cause. Estimates were classified as TTP if the event of interest was defined as disease progression, which may also include cause‐specific death from breast cancer. In instances where the event of interest was ambiguously defined or not defined at all, we relied on the authors label of the outcome for classifying as PFS or TTP. </p> <p>Lastly, to assess the sensitivity of our primary results to our choice of analytical method, we repeated <a href="./references#CD003374-fig-0007" title="">Analysis 1.1</a>, <a href="./references#CD003374-fig-0008" title="">Analysis 1.2</a> and <a href="./references#CD003374-fig-0009" title="">Analysis 1.3</a> but using random‐effects rather than fixed‐effect methods. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003374-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003374-sec-0059"></div> <section id="CD003374-sec-0060"> <h3 class="title">Description of studies</h3> <section id="CD003374-sec-0061"> <h4 class="title">Results of the search</h4> <p>For the 2016 review update, we reviewed 1644 unique records identified by the May 2015 database searches (<a href="#CD003374-fig-0001">Figure 1</a>). Of these, 1610 could be excluded based on information in the title or abstract, and nine records from trial registries or protocol publications were considered to be potentially relevant ongoing studies yet to publish results (see <a href="./references#CD003374-sec-0114" title="">Characteristics of ongoing studies</a>). For the remaining 25 records, we retrieved full‐text articles or abstracts for further examination. Eight of the 25 articles or abstracts were excluded because they were reviews (but these were still used to search for further studies by handsearching the bibliographies) and three other full‐text articles were excluded for reasons outlined in the <a href="./references#CD003374-sec-0113" title="">Characteristics of excluded studies</a> table. </p> <div class="figure" id="CD003374-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Review update 2016: study flow diagram." data-id="CD003374-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review update 2016: study flow diagram.</p> </div> </div> </div> </section> <section id="CD003374-sec-0062"> <h4 class="title">Included studies</h4> <p>Fourteen studies containing 17 treatment‐comparisons with sufficient data to be included in one or more pooled analyses were identified by this review update. Of these 17 treatment‐comparisons, two had been included in the original review but had since published updated results (Icli 2002 and Fountzilas 2002 in the original review were renamed <a href="./references#CD003374-bbs2-0018" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP‐16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002; Vol. 13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639‐44. ">Icli 2005</a> and <a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a> in this review update), and 15 were new to the review (<a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a> ;<a href="./references#CD003374-bbs2-0004" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple‐negative. European Journal of Cancer Supplements. 2009; Vol. 7, issue 3:18‐19. ">Bhattacharyya 2009</a>; <a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD003374-bbs2-0013" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first‐line treatment of metastatic triple‐negative breast cancer. Annals of Oncology2013;24(5):1219‐25. ">Fan 2012</a>; <a href="./references#CD003374-bbs2-0011" title="DelalogeS , Tubiana‐HulinM , WardleyA , DelMastroL , SantoroA , ZambelliA , et al. A multistep randomized phase II/III trial comparing Oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN) + FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results. Journal of Clinical Oncology. 2004; Vol. 22 Supplement:14S. ">Delaloge 2004</a>; <a href="./references#CD003374-bbs2-0015" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 A</a>; <a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a>; <a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a>; <a href="./references#CD003374-bbs2-0022" title="RobertN , Leyland‐JonesB , AsmarL , BeltR , IlegboduD , LoeschD , et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER‐2‐overexpressing metastatic breast cancer. Journal of Clinical Oncology2006;24(18):2786‐92. ">Robert 2006</a>; <a href="./references#CD003374-bbs2-0023" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 A</a>; <a href="./references#CD003374-bbs2-0024" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 B</a>; <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a>; <a href="./references#CD003374-bbs2-0026" title="ForbesJF , PienkowskiT , ValeroV , EiermannW , VonMinckwitzG , MartinM , et al. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first‐line in HER2 positive metastatic breast cancer (MBC). Journal of Clinical Oncology2006;24(Supplement):18S. NCT00047255 . Docetaxel and trastuzumab with or without carboplatin in treating women with HER2‐positive breast cancer. clinicaltrials.gov/ct2/show/NCT00047255 (accessed 13 April 2016). ValeroV , ForbesJ , PegramMD , PienkowskiT , EiermannW , VonMinckwitzG , et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first‐line chemotherapy for patients with HER2‐gene‐amplified metastatic breast cancer (BCIRG 007 Study): Two highly active therapeutic regimens. Journal of Clinical Oncology2011;29(2):149‐56. ">Valero 2011</a>; <a href="./references#CD003374-bbs2-0027" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 A</a>; <a href="./references#CD003374-bbs2-0028" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 B</a>). Overall, the review now includes results from 24 studies corresponding to 28 treatment‐comparisons (see <a href="./references#CD003374-sec-0112" title="">Characteristics of included studies</a>). </p> <p>Of the 28 treatment‐comparisons included in this review update (<a href="#CD003374-tbl-0006">Table 3</a>): </p> <div class="table" id="CD003374-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of treatment‐comparisons included in meta‐analyses by subgroup and three outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐</b> </p> <p><b>comparisons</b> </p> <p><b>N</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall</b> </p> <p><b>survival</b> </p> <p><b>n (% of N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression</b> </p> <p><b>‐free</b> </p> <p><b>survival/time to</b> </p> <p><b>progression</b> </p> <p><b>n (% of N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objective</b> </p> <p><b>response</b> </p> <p><b>rate</b> </p> <p><b>n (% of N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall:</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (68%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (57%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of platinum agent in platinum arm:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin in platinum arm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (65%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (65%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin in platinum arm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (80%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxaliplatin in platinum arm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of regimen comparison:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regimen A + platinum agent vs regimen A</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (67%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (67%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regimen A + platinum agent vs regimen B</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (72%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (56%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single agent platinum vs regimen C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>First‐line therapy:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First‐line therapy for &gt; 80% of participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (75%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (55%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Second‐ or third‐line therapy for ≥ 20% of participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (63%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant selection for mTNBC:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with mTNBC</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (60%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (60%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants unselected for mTNBC</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (70%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (57%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anthracycline in regimens:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No anthracycline in platinum or non‐platinum regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (78%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (61%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum + anthracycline vs non‐platinum + anthracycline regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (67%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum + anthracycline vs non‐platinum + non‐anthracycline regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (25%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Taxane in regimens:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No taxane in platinum or non‐platinum regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (53%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (53%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum + taxane vs non‐platinum + taxane regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum + non‐taxane vs non‐platinum + taxane regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (80%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (80%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trastuzumab in regimens:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trastuzumab in platinum or non‐platinum regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (65%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (54%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum + trastuzumab vs non‐platinum + trastuzumab regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (100%)</p> </td> </tr> </tbody> </table> </div> <p> <ul id="CD003374-list-0006"> <li> <p>17 (61%) used cisplatin, 10 (36%) used carboplatin and one (4%) used oxaliplatin as the platinum agent in the intervention arm; </p> </li> <li> <p>9 (32%) compared 'regimen A + platinum vs regimen A', 18 (64%) compared 'regimen A + platinum vs regimen B' and one (4%) compared single agent platinum vs regimen C' (<a href="#CD003374-tbl-0007">Table 4</a>); </p> </li> <li> <p>20 (71%) had more than 80% of participants receiving first‐line therapy;</p> </li> <li> <p>5 (18%) were designed to assess participants with mTNBC;</p> </li> <li> <p>18 (64%) had no anthracycline in the platinum or non‐platinum regimens, six (21%) had an anthracycline in both regimens, and four (14%) had an anthracycline in the platinum regimen only; </p> </li> <li> <p>17 (61%) had no taxane in the platinum or non‐platinum regimens; six (21%) had a taxane in both regimens and five (18%) had a taxane in the non‐platinum regimen only; </p> </li> <li> <p>26 (93%) had no trastuzumab in the platinum or non‐platinum regimens and two (7%) had a trastuzumab in both regimens. </p> </li> </ul> </p> <div class="table" id="CD003374-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of regimens included in the analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trials ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arm 1 (platinum‐containing)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arm 2 (control)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>First‐line therapy for &gt; 80% of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Majority participants anthracycline‐naive</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen A</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0002" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + Cis (epirubicin+cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi (epirubicin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0003" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + Cis + LND (epirubicin+cisplatin+lonidamine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + LND (epirubicin + lonidamine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0004" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple‐negative. European Journal of Cancer Supplements. 2009; Vol. 7, issue 3:18‐19. ">Bhattacharyya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endoxan 50 mg per day at 10 am and methotrexate 2.5 mg twice a day at 9 am and 5 pm and with 'cisplatinum' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endoxan 50 mg per day at 10 am and methotrexate 2.5 mg twice a day at 9 am and 5 pm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C + Cb (Cetuximab + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C (Cetuximab with carboplatin added after progression)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0009" title="CostanzaME , WeissRB , HendersonIC , NortonL , BerryDA , CirrincioneC , et al. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study‐‐Cancer and Leukemia Group B 8642. Journal of Clinical Oncology1999;17(5):1397‐406. ">Costanza 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBDA + CAF (carboplatin + cycloheximide + doxorubicin + fluorouracil + methotrexate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAF (cycloheximide + doxorubicin + fluorouracil)</p> <p>(methotrexate substituted after total doxorubicin ‐ 540 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0015" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCb (paclitaxel + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pw (paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0021" title="NielsenD , DombernowskyP , LarsenSK , HansenOP , SkovsgaardT . Epirubicin or epirubicin and cisplatin as first‐line therapy in advanced breast cancer. A phase III study. Cancer Chemotherapy &amp; Pharmacology2000;46(6):459‐66. RybergM , NielsenD , SkovsgaardT , HansenJ , JensenBV , DombernowskyP . Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. Journal of Clinical Oncology1998;16(11):3502‐8. ">Nielsen 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + Cis (epirubicin + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi (epirubicin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0022" title="RobertN , Leyland‐JonesB , AsmarL , BeltR , IlegboduD , LoeschD , et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER‐2‐overexpressing metastatic breast cancer. Journal of Clinical Oncology2006;24(18):2786‐92. ">Robert 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TPC (trastuzumab + paclitaxel + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TP (trastuzumab + paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0026" title="ForbesJF , PienkowskiT , ValeroV , EiermannW , VonMinckwitzG , MartinM , et al. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first‐line in HER2 positive metastatic breast cancer (MBC). Journal of Clinical Oncology2006;24(Supplement):18S. NCT00047255 . Docetaxel and trastuzumab with or without carboplatin in treating women with HER2‐positive breast cancer. clinicaltrials.gov/ct2/show/NCT00047255 (accessed 13 April 2016). ValeroV , ForbesJ , PegramMD , PienkowskiT , EiermannW , VonMinckwitzG , et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first‐line chemotherapy for patients with HER2‐gene‐amplified metastatic breast cancer (BCIRG 007 Study): Two highly active therapeutic regimens. Journal of Clinical Oncology2011;29(2):149‐56. ">Valero 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TCH (trastuzumab + docetaxel + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TH (trastuzumab + docetaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen B</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(pemetrexed + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(vinorelbine + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0006" title="CocconiG , BisagniG , BacchiM , BoniC , BartolucciR , CeciG , et al. Cisplatin and etoposide as first‐line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology1991;9(4):664‐9. ">Cocconi 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MPEPIV(a) or MPEMi (b) (a<i>:</i> methotrexate, leucovorin, cisplatin, epirubicin, vincristine; b: methotrexate, leucovorin, cisplatin, etoposide, mitomycin) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMF (cyclophosphamide, methotrexate, fluorouracil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0007" title="CocconiG , BellaM , BartolucciR , BasurtoC , ColozzaM , IndelliM . Continuous CMF compared to a short chemotherapy using cisplatin‐containing combinations in metastatic breast carcinoma. A prospective randomized study. Annals of Oncology1996;7(Suppl 5):22. ">Cocconi 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Etop + Cis (etoposide + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMF (cyclophosphamide, methotrexate, fluorouracil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0008" title="CocconiG , BisagniG , BellaM , AcitoL , AnastasiP , CarpiA , et al. Comparison of CMF (cyclophosphamide, methotrexate, and 5‐fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. American Journal of Clinical Oncology1999;22(6):593‐600. ">Cocconi 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PE + CMF + AL (cisplatin + etoposide + doxorubicin + cyclophosphamide, methotrexate + fluorouracil, lecovorin + allopurinol) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMF (cyclophosphamide, methotrexate, fluorouracil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0010" title="CreaganET , GreenSJ , AhmannDL , IngleJN , EdmonsonJH , MarschkeRF‐J . A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5‐ fluorouracil, prednisone in patients with advanced breast cancer. Journal of Clinical Oncology1984;2(11):1260‐5. ">Creagan 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CFP + CAP (cyclophosphamide + doxorubicin + cis‐dichlordiammine + CFP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CFP (cyclophosphamide + fluorouracil + prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0011" title="DelalogeS , Tubiana‐HulinM , WardleyA , DelMastroL , SantoroA , ZambelliA , et al. A multistep randomized phase II/III trial comparing Oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN) + FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results. Journal of Clinical Oncology. 2004; Vol. 22 Supplement:14S. ">Delaloge 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OXA (oxaliplatin + 5‐flurouracil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIN (vinorelbine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0012" title="EisenT , SmithIE , DeBoerR , EllisPA . A randomised phase II trial of infusional 5‐FU and epirubicin with cyclophosphamide versus cisplatin in advanced breast cancer. Breast Cancer Research &amp; Treatment1997;46(1):94. EisenT , SmithIE , JohnstonS , EllisPA , PrendivilleJ , SeymourMT , et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. Journal of Clinical Oncology1998;16(4):1350‐7. ">Eisen 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EcisF (5‐flurouracil + epirubicin + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EcycloF (5‐flurouracil + epirubicin + cyclophosphamide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0013" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first‐line treatment of metastatic triple‐negative breast cancer. Annals of Oncology2013;24(5):1219‐25. ">Fan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TP (docetaxel + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TX (docetaxel + capecitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + Pcb (epirubicin + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + P (epirubicin + paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y (54%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCb (paclitaxel + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDoc (docetaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(cisplatin + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(paclitaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0018" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP‐16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002; Vol. 13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639‐44. ">Icli 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Etop + Cis (etoposide + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P (paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0019" title="KolaricK , VukasD , RothA , PotrebicaV , CervekJ , CerarO . Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report. Tumori1985;71:159‐65. ">Kolaric 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAP (cyclophosphamide + doxorubicin + platinum)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMFVP (cyclophosphamide + methotrexate + 5‐fluorouracil + vincristine + prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0020" title="KolaricK , VukasD , PotrebicaV . Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5‐fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. Tumori1989;75:132‐6. ">Kolaric 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAP (cyclophosphamide + doxorubicin +platinum)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FAC (5‐flurouracil + doxorubicin +</p> <p>cyclophosphamide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0023" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCis (gemcitabine + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemVin (gemcitabine + vinorelbine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0024" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCis (gemcitabine + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCap (gemcitabine + capecitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0027" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCis (gemcitabine + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemPac (gemcitabine + paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0028" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCarb (gemcitabine + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemPac (gemcitabine + paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Single agent platinum vs regimen C</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C (carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D (docetaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> </tbody> </table> </div> <p>Not all the studies provided sufficient information on all outcomes for inclusion in meta‐analyses. Of the 28 treatment‐comparisons: </p> <p> <ul id="CD003374-list-0007"> <li> <p>19 (68%), 16 (57%) and 28 (100%) had sufficient data to be included in the meta‐analyses of effect estimates for OS, PFS/TTP and OTRR, respectively (<a href="#CD003374-tbl-0006">Table 3</a> and <a href="#CD003374-fig-0001">Figure 1</a>); </p> </li> <li> <p>15 (54%), 21 (75%), 5 (18%), 20 (71%), 12 (43%) and 22 (79%) had sufficient data to be included in the meta‐analyses of effect estimates for treatment‐related death, nausea/vomiting, nephrotoxicity, anaemia, hair loss, and leukopenia, respectively (<a href="#CD003374-tbl-0008">Table 5</a> and <a href="#CD003374-fig-0001">Figure 1</a>). </p> </li> </ul> </p> <div class="table" id="CD003374-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of outcomes for included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Extractable OS data for HR estimation<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median OS time<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Extractable PFS/TTP data for HR estimation<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median PFS/TTP time<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment‐related deaths</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade III &amp; IV Toxicity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Accrual<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen A</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0002" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Nephrotoxicity</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>185</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0003" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Nephrotoxicity</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0004" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple‐negative. European Journal of Cancer Supplements. 2009; Vol. 7, issue 3:18‐19. ">Bhattacharyya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>126</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not extractable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0009" title="CostanzaME , WeissRB , HendersonIC , NortonL , BerryDA , CirrincioneC , et al. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study‐‐Cancer and Leukemia Group B 8642. Journal of Clinical Oncology1999;17(5):1397‐406. ">Costanza 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>221</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0015" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0021" title="NielsenD , DombernowskyP , LarsenSK , HansenOP , SkovsgaardT . Epirubicin or epirubicin and cisplatin as first‐line therapy in advanced breast cancer. A phase III study. Cancer Chemotherapy &amp; Pharmacology2000;46(6):459‐66. RybergM , NielsenD , SkovsgaardT , HansenJ , JensenBV , DombernowskyP . Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. Journal of Clinical Oncology1998;16(11):3502‐8. ">Nielsen 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0022" title="RobertN , Leyland‐JonesB , AsmarL , BeltR , IlegboduD , LoeschD , et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER‐2‐overexpressing metastatic breast cancer. Journal of Clinical Oncology2006;24(18):2786‐92. ">Robert 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0026" title="ForbesJF , PienkowskiT , ValeroV , EiermannW , VonMinckwitzG , MartinM , et al. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first‐line in HER2 positive metastatic breast cancer (MBC). Journal of Clinical Oncology2006;24(Supplement):18S. NCT00047255 . Docetaxel and trastuzumab with or without carboplatin in treating women with HER2‐positive breast cancer. clinicaltrials.gov/ct2/show/NCT00047255 (accessed 13 April 2016). ValeroV , ForbesJ , PegramMD , PienkowskiT , EiermannW , VonMinckwitzG , et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first‐line chemotherapy for patients with HER2‐gene‐amplified metastatic breast cancer (BCIRG 007 Study): Two highly active therapeutic regimens. Journal of Clinical Oncology2011;29(2):149‐56. ">Valero 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen B</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0006" title="CocconiG , BisagniG , BacchiM , BoniC , BartolucciR , CeciG , et al. Cisplatin and etoposide as first‐line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology1991;9(4):664‐9. ">Cocconi 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0008" title="CocconiG , BisagniG , BellaM , AcitoL , AnastasiP , CarpiA , et al. Comparison of CMF (cyclophosphamide, methotrexate, and 5‐fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. American Journal of Clinical Oncology1999;22(6):593‐600. ">Cocconi 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0007" title="CocconiG , BellaM , BartolucciR , BasurtoC , ColozzaM , IndelliM . Continuous CMF compared to a short chemotherapy using cisplatin‐containing combinations in metastatic breast carcinoma. A prospective randomized study. Annals of Oncology1996;7(Suppl 5):22. ">Cocconi 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not extractable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0010" title="CreaganET , GreenSJ , AhmannDL , IngleJN , EdmonsonJH , MarschkeRF‐J . A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5‐ fluorouracil, prednisone in patients with advanced breast cancer. Journal of Clinical Oncology1984;2(11):1260‐5. ">Creagan 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0011" title="DelalogeS , Tubiana‐HulinM , WardleyA , DelMastroL , SantoroA , ZambelliA , et al. A multistep randomized phase II/III trial comparing Oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN) + FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results. Journal of Clinical Oncology. 2004; Vol. 22 Supplement:14S. ">Delaloge 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not extractable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0012" title="EisenT , SmithIE , DeBoerR , EllisPA . A randomised phase II trial of infusional 5‐FU and epirubicin with cyclophosphamide versus cisplatin in advanced breast cancer. Breast Cancer Research &amp; Treatment1997;46(1):94. EisenT , SmithIE , JohnstonS , EllisPA , PrendivilleJ , SeymourMT , et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. Journal of Clinical Oncology1998;16(4):1350‐7. ">Eisen 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0013" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first‐line treatment of metastatic triple‐negative breast cancer. Annals of Oncology2013;24(5):1219‐25. ">Fan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>212</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0018" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP‐16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002; Vol. 13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639‐44. ">Icli 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0019" title="KolaricK , VukasD , RothA , PotrebicaV , CervekJ , CerarO . Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report. Tumori1985;71:159‐65. ">Kolaric 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Nephrotoxicity</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0020" title="KolaricK , VukasD , PotrebicaV . Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5‐fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. Tumori1989;75:132‐6. ">Kolaric 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0023" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0024" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0027" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Nephrotoxicity</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0028" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Nephrotoxicity</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Single agent platinum vs regimen C</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>376</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Sufficient data reported to estimate a HR for pooling as outlined by <a href="./references#CD003374-bbs2-0063" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815‐34. ">Parmar 1998</a> and <a href="./references#CD003374-bbs2-0069" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8(1):1. ">Tierney 2007</a>; this includes Kapalan‐Meier curve, HR and standard error/confidence interval or logrank statistics </p> <p><sup>2</sup> Trials that did not explicitly report median time were classified as NR here regardless of estimable median time from Kaplan‐Meier curve </p> <p><sup>3</sup> Accrual numbers represent the maximum numbers of participants in the trial (not study) that were included in the analyses of OS, PFS/TTP or OR (assessable participants). </p> <p>*NR = not reported, DU = deaths unexplained, Y = data reported.</p> </div> </div> <p>Three studies reported treatment effects on various quality of life domains (<a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a>; Fountzilas 2009: <a href="./references#CD003374-bbs2-0015" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 A</a> &amp; <a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a>; <a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a>) but these results could not be pooled in a meta‐analysis. Three studies reported TTF results (<a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a>; <a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a>; Xu: <a href="./references#CD003374-bbs2-0027" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 A</a> &amp; <a href="./references#CD003374-bbs2-0028" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 B</a>), but these data were only extractable for <a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a>. </p> </section> <section id="CD003374-sec-0063"> <h4 class="title">Excluded studies</h4> <p>In this review update, seven studies may have appeared to have met the eligibility criteria, but were deemed ineligible for reasons given in the <a href="./references#CD003374-sec-0113" title="">Characteristics of excluded studies</a> table. Of these seven excluded studies: two were registered trials that were previously listed as 'ongoing studies' in the original review but were reclassified as 'excluded' in this review update because the principal investigator had informed us that the trials never commenced (<a href="./references#CD003374-bbs2-0032" title="NCT00025688 . A randomized, phase II trial of weekly taxol (paclitaxel) versus weekly taxol plus paraplatin (carboplatin) as first‐line chemotherapy in patients age 65 years or older with metastatic breast cancer. clinicaltrials.gov/ct2/show/study/NCT00025688 (accessed April 12 2016). ">Perez 2001</a>; <a href="./references#CD003374-bbs2-0033" title="PerezEA . Phase III randomized study of Paclitaxel, Carboplatin, and Trastuzumab (Herceptin) as first‐line chemotherapy in women with overexpressed HER‐2, metastatic breast cancer. www.cancer.gov/clinical trials 2002. ">Perez 2002</a>); two were 'excluded studies' in the original review and remained so in this review update (<a href="./references#CD003374-bbs2-0029" title="Cartei , MPP . Epirubicin versus platin and etoposide: A cross over study in breast cancer. Tumori. 1996; Vol. 82, issue Supplement:125. ">Cartei 1996</a>; <a href="./references#CD003374-bbs2-0031" title="HogdallCK , SoletormosG , NielsenD , NorgaardPB , DombernowskyP , ClemmensenI . Prognostic value of serum tetranectin in patients with metastatic breast cancer. Acta Oncologica1993;32:631‐6. ">Hogdall 1993</a>); and three were newly identified in this review update (<a href="./references#CD003374-bbs2-0030" title="CrumpM , GluckS , TuD , StewartD , LevineM , KirkbrideP , et al. Randomized trial of high‐dose chemotherapy with autologous peripheral‐blood stem‐cell support compared with standard‐dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. Journal of Clinical Oncology2008;26(1):37‐43. ">Crump 2008</a>; <a href="./references#CD003374-bbs2-0034" title="SomloG , FrankelPH , LuuTH , MaCX , ArunB , GarciaAA , et al. Efficacy of the PARP inhibitor (PI) ABT‐888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post‐progression therapy in combination with carb in patients (pts) with BRCA1‐or BRCA2‐(BRCA)‐associated metastatic breast cancer (MBC). Journal of Clinical Oncology2015;33(15 Suppl):520. ">Somlo 2015</a>; <a href="./references#CD003374-bbs2-0035" title="WangY , WuQ , SuF , ZhouL , YeZ , YangJ , et al. Phase II study of docetaxel plus epirubicin versus docetaxel plus cisplatin as first‐line chemotherapy for metastatic breast cancer. Chinese Journal of Oncology2008;30(7):541‐4. ">Wang 2008</a>). Two other studies listed as 'excluded' in the original review ('Eisen' and 'Ryberg 1998') were removed from the excluded studies section altogether in this review update as they referred to earlier reports of studies that were actually included in the original review (<a href="./references#CD003374-bbs2-0012" title="EisenT , SmithIE , DeBoerR , EllisPA . A randomised phase II trial of infusional 5‐FU and epirubicin with cyclophosphamide versus cisplatin in advanced breast cancer. Breast Cancer Research &amp; Treatment1997;46(1):94. EisenT , SmithIE , JohnstonS , EllisPA , PrendivilleJ , SeymourMT , et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. Journal of Clinical Oncology1998;16(4):1350‐7. ">Eisen 1998</a>; <a href="./references#CD003374-bbs2-0021" title="NielsenD , DombernowskyP , LarsenSK , HansenOP , SkovsgaardT . Epirubicin or epirubicin and cisplatin as first‐line therapy in advanced breast cancer. A phase III study. Cancer Chemotherapy &amp; Pharmacology2000;46(6):459‐66. RybergM , NielsenD , SkovsgaardT , HansenJ , JensenBV , DombernowskyP . Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. Journal of Clinical Oncology1998;16(11):3502‐8. ">Nielsen 2000</a>). </p> </section> </section> <section id="CD003374-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD003374-fig-0002">Figure 2</a> shows a summary of the 'Risk of bias' judgements for each 'Risk of bias' domain of the included treatment‐comparisons. Reasons for each judgement are detailed for each treatment‐comparison in the <a href="./references#CD003374-sec-0112" title="">Characteristics of included studies</a> table. For each 'risk of bias' domain, a summary of the general risk of bias for results of the included studies was as follows. </p> <div class="figure" id="CD003374-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003374-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003374-sec-0065"> <h4 class="title">Allocation</h4> <p>All 24 studies, relating to 28 treatment‐comparisons, were described as randomised (this being an inclusion criterion of the review). The method of random sequence generation was described sufficiently to be judged at low risk of bias for this domain in 5 treatment‐comparisons (<a href="./references#CD003374-bbs2-0004" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple‐negative. European Journal of Cancer Supplements. 2009; Vol. 7, issue 3:18‐19. ">Bhattacharyya 2009</a>; <a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a>; <a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a>; <a href="./references#CD003374-bbs2-0026" title="ForbesJF , PienkowskiT , ValeroV , EiermannW , VonMinckwitzG , MartinM , et al. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first‐line in HER2 positive metastatic breast cancer (MBC). Journal of Clinical Oncology2006;24(Supplement):18S. NCT00047255 . Docetaxel and trastuzumab with or without carboplatin in treating women with HER2‐positive breast cancer. clinicaltrials.gov/ct2/show/NCT00047255 (accessed 13 April 2016). ValeroV , ForbesJ , PegramMD , PienkowskiT , EiermannW , VonMinckwitzG , et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first‐line chemotherapy for patients with HER2‐gene‐amplified metastatic breast cancer (BCIRG 007 Study): Two highly active therapeutic regimens. Journal of Clinical Oncology2011;29(2):149‐56. ">Valero 2011</a>). The remaining 23 treatment‐comparisons were judged to be at unclear risk of bias for random sequence generation as the information available was insufficient to accurately assess this domain. </p> <p>Eight of the 28 treatment‐comparisons described central randomisation systems and were thus judged to be at low risk of bias for treatment allocation concealment (<a href="./references#CD003374-bbs2-0006" title="CocconiG , BisagniG , BacchiM , BoniC , BartolucciR , CeciG , et al. Cisplatin and etoposide as first‐line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology1991;9(4):664‐9. ">Cocconi 1991</a>; <a href="./references#CD003374-bbs2-0008" title="CocconiG , BisagniG , BellaM , AcitoL , AnastasiP , CarpiA , et al. Comparison of CMF (cyclophosphamide, methotrexate, and 5‐fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. American Journal of Clinical Oncology1999;22(6):593‐600. ">Cocconi 1999</a>; <a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a>; <a href="./references#CD003374-bbs2-0015" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 A</a>; <a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a>; <a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a>; <a href="./references#CD003374-bbs2-0018" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP‐16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002; Vol. 13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639‐44. ">Icli 2005</a>; <a href="./references#CD003374-bbs2-0021" title="NielsenD , DombernowskyP , LarsenSK , HansenOP , SkovsgaardT . Epirubicin or epirubicin and cisplatin as first‐line therapy in advanced breast cancer. A phase III study. Cancer Chemotherapy &amp; Pharmacology2000;46(6):459‐66. RybergM , NielsenD , SkovsgaardT , HansenJ , JensenBV , DombernowskyP . Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. Journal of Clinical Oncology1998;16(11):3502‐8. ">Nielsen 2000</a>). The remaining 20 treatment‐comparisons did not adequately describe methods of concealment and were thus judged as having unclear risk of bias for this domain. </p> </section> <section id="CD003374-sec-0066"> <h4 class="title">Blinding</h4> <p>Eleven treatment‐comparisons were described as 'nonblinded', 'not blinded', 'single blind' or 'open‐label' (<a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a>; <a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD003374-bbs2-0013" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first‐line treatment of metastatic triple‐negative breast cancer. Annals of Oncology2013;24(5):1219‐25. ">Fan 2012</a>; <a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a>; <a href="./references#CD003374-bbs2-0018" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP‐16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002; Vol. 13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639‐44. ">Icli 2005</a>; <a href="./references#CD003374-bbs2-0023" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 A</a>; <a href="./references#CD003374-bbs2-0024" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 B</a>; <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a>; <a href="./references#CD003374-bbs2-0026" title="ForbesJF , PienkowskiT , ValeroV , EiermannW , VonMinckwitzG , MartinM , et al. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first‐line in HER2 positive metastatic breast cancer (MBC). Journal of Clinical Oncology2006;24(Supplement):18S. NCT00047255 . Docetaxel and trastuzumab with or without carboplatin in treating women with HER2‐positive breast cancer. clinicaltrials.gov/ct2/show/NCT00047255 (accessed 13 April 2016). ValeroV , ForbesJ , PegramMD , PienkowskiT , EiermannW , VonMinckwitzG , et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first‐line chemotherapy for patients with HER2‐gene‐amplified metastatic breast cancer (BCIRG 007 Study): Two highly active therapeutic regimens. Journal of Clinical Oncology2011;29(2):149‐56. ">Valero 2011</a>; <a href="./references#CD003374-bbs2-0027" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 A</a>; <a href="./references#CD003374-bbs2-0028" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 B</a>). These 11 'unblinded' treatment‐comparisons were judged to be at high risk of 'performance bias' due to the lack of blinding of participants and personnel to the treatment being administered. The remaining 17 treatment‐comparisons were judged as at unclear risk of 'performance bias' because of a lack of information needed to make a firm conclusion. It seemed highly likely, however, that a number of these 17 treatment‐comparisons would have also been 'unblinded', as open‐label studies are common in phase III oncology trials. </p> <p>All 27 treatment‐comparisons known to have OS as a study outcome (including 8 not included in OS meta‐analyses but excluding <a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a> which did not assess OS as an outcome) were judged to be at low risk of bias from a lack of blinding of outcome assessors, regardless of actual blinding. This is because death certification was unlikely to be affected by any lack of blinding. </p> <p>For outcomes other than OS and QoL, five treatment‐comparisons were judged to be at low risk of bias from a lack of blinding of outcome assessors due to these outcomes being measured/confirmed through formal assessments including imaging, biochemical tests and/or the involvement of an independent clinical or radiological review group (<a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD003374-bbs2-0006" title="CocconiG , BisagniG , BacchiM , BoniC , BartolucciR , CeciG , et al. Cisplatin and etoposide as first‐line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology1991;9(4):664‐9. ">Cocconi 1991</a>; <a href="./references#CD003374-bbs2-0008" title="CocconiG , BisagniG , BellaM , AcitoL , AnastasiP , CarpiA , et al. Comparison of CMF (cyclophosphamide, methotrexate, and 5‐fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. American Journal of Clinical Oncology1999;22(6):593‐600. ">Cocconi 1999</a>; <a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a>; <a href="./references#CD003374-bbs2-0018" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP‐16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002; Vol. 13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639‐44. ">Icli 2005</a>). The remaining 23 treatment‐comparisons provided insufficient detail on outcome assessments and were thus classified as having an unclear risk of bias. </p> </section> <section id="CD003374-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>Three treatment‐comparisons were judged to be at high risk of attrition bias for time‐to‐event outcomes because participants who did not receive a specified number of cycles of chemotherapy were excluded from time‐to‐event analyses (a form of per‐protocol analysis) (<a href="./references#CD003374-bbs2-0019" title="KolaricK , VukasD , RothA , PotrebicaV , CervekJ , CerarO . Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report. Tumori1985;71:159‐65. ">Kolaric 1985</a>; <a href="./references#CD003374-bbs2-0020" title="KolaricK , VukasD , PotrebicaV . Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5‐fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. Tumori1989;75:132‐6. ">Kolaric 1989</a>; <a href="./references#CD003374-bbs2-0021" title="NielsenD , DombernowskyP , LarsenSK , HansenOP , SkovsgaardT . Epirubicin or epirubicin and cisplatin as first‐line therapy in advanced breast cancer. A phase III study. Cancer Chemotherapy &amp; Pharmacology2000;46(6):459‐66. RybergM , NielsenD , SkovsgaardT , HansenJ , JensenBV , DombernowskyP . Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. Journal of Clinical Oncology1998;16(11):3502‐8. ">Nielsen 2000</a>). Eleven treatment‐comparisons excluded randomised participants who never started treatment or who were subsequently found to have been 'ineligible' from time‐to‐event analyses (mITT analyses) (<a href="./references#CD003374-bbs2-0002" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 A</a>; <a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD003374-bbs2-0008" title="CocconiG , BisagniG , BellaM , AcitoL , AnastasiP , CarpiA , et al. Comparison of CMF (cyclophosphamide, methotrexate, and 5‐fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. American Journal of Clinical Oncology1999;22(6):593‐600. ">Cocconi 1999</a>; <a href="./references#CD003374-bbs2-0007" title="CocconiG , BellaM , BartolucciR , BasurtoC , ColozzaM , IndelliM . Continuous CMF compared to a short chemotherapy using cisplatin‐containing combinations in metastatic breast carcinoma. A prospective randomized study. Annals of Oncology1996;7(Suppl 5):22. ">Cocconi 1996</a>; <a href="./references#CD003374-bbs2-0010" title="CreaganET , GreenSJ , AhmannDL , IngleJN , EdmonsonJH , MarschkeRF‐J . A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5‐ fluorouracil, prednisone in patients with advanced breast cancer. Journal of Clinical Oncology1984;2(11):1260‐5. ">Creagan 1984</a>; <a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a>; <a href="./references#CD003374-bbs2-0015" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 A</a>; <a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a>; <a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a>; <a href="./references#CD003374-bbs2-0018" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP‐16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002; Vol. 13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639‐44. ">Icli 2005</a>; <a href="./references#CD003374-bbs2-0027" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 A</a>). These 11 treatment‐comparisons were judged to be at unclear risk of attrition bias for time‐to‐event outcomes. The remaining 14 treatment‐comparisons were judged to be at low risk of attrition bias for time‐to‐event outcomes because all randomised participants were analysed in the groups to which they were randomised (ITT analysis). </p> <p>Four treatment‐comparisons had more than 15% of participants not assessed/assessable for at least one binary outcome and were thus judged to be at high risk of attrition bias for binary outcomes (<a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a>; <a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a>; <a href="./references#CD003374-bbs2-0023" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 A</a>; <a href="./references#CD003374-bbs2-0024" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 B</a>; ). Fourteen treatment‐comparisons had less than 10% of participants not assessed/assessable for all binary outcomes and were thus judged to be at low risk of attrition bias for binary outcomes (<a href="./references#CD003374-bbs2-0002" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 A</a>; <a href="./references#CD003374-bbs2-0003" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 B</a>; <a href="./references#CD003374-bbs2-0006" title="CocconiG , BisagniG , BacchiM , BoniC , BartolucciR , CeciG , et al. Cisplatin and etoposide as first‐line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology1991;9(4):664‐9. ">Cocconi 1991</a>; <a href="./references#CD003374-bbs2-0008" title="CocconiG , BisagniG , BellaM , AcitoL , AnastasiP , CarpiA , et al. Comparison of CMF (cyclophosphamide, methotrexate, and 5‐fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. American Journal of Clinical Oncology1999;22(6):593‐600. ">Cocconi 1999</a>; <a href="./references#CD003374-bbs2-0010" title="CreaganET , GreenSJ , AhmannDL , IngleJN , EdmonsonJH , MarschkeRF‐J . A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5‐ fluorouracil, prednisone in patients with advanced breast cancer. Journal of Clinical Oncology1984;2(11):1260‐5. ">Creagan 1984</a>; <a href="./references#CD003374-bbs2-0013" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first‐line treatment of metastatic triple‐negative breast cancer. Annals of Oncology2013;24(5):1219‐25. ">Fan 2012</a>; <a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a>; <a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a>; <a href="./references#CD003374-bbs2-0018" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP‐16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002; Vol. 13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639‐44. ">Icli 2005</a>; <a href="./references#CD003374-bbs2-0019" title="KolaricK , VukasD , RothA , PotrebicaV , CervekJ , CerarO . Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report. Tumori1985;71:159‐65. ">Kolaric 1985</a>; <a href="./references#CD003374-bbs2-0022" title="RobertN , Leyland‐JonesB , AsmarL , BeltR , IlegboduD , LoeschD , et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER‐2‐overexpressing metastatic breast cancer. Journal of Clinical Oncology2006;24(18):2786‐92. ">Robert 2006</a>; <a href="./references#CD003374-bbs2-0026" title="ForbesJF , PienkowskiT , ValeroV , EiermannW , VonMinckwitzG , MartinM , et al. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first‐line in HER2 positive metastatic breast cancer (MBC). Journal of Clinical Oncology2006;24(Supplement):18S. NCT00047255 . Docetaxel and trastuzumab with or without carboplatin in treating women with HER2‐positive breast cancer. clinicaltrials.gov/ct2/show/NCT00047255 (accessed 13 April 2016). ValeroV , ForbesJ , PegramMD , PienkowskiT , EiermannW , VonMinckwitzG , et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first‐line chemotherapy for patients with HER2‐gene‐amplified metastatic breast cancer (BCIRG 007 Study): Two highly active therapeutic regimens. Journal of Clinical Oncology2011;29(2):149‐56. ">Valero 2011</a>; <a href="./references#CD003374-bbs2-0027" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 A</a>; <a href="./references#CD003374-bbs2-0028" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 B</a>). The remaining 10 treatment‐comparisons were judged to be at unclear risk of attrition bias for binary outcomes (10 to 15% of participants not assessed/assessable for at least one binary outcome or it was unclear what proportion were not assessed). </p> </section> <section id="CD003374-sec-0068"> <h4 class="title">Selective reporting</h4> <p>The assessment of risk of bias from selective reporting included crosschecking the outcomes for which there were published results against the stated outcomes reported in trial registers (WHO ICTRP and ClinicalTrials.gov) and published protocols. In our assessment of risk of bias from selective reporting, studies that began recruiting participants on or after July 1, 2005 were expected have a clinical registration or published protocol specifying the study outcome or they were deemed to be at high risk of bias from selective reporting. We chose July 1, 2005 as our cut‐off date because the International Committee of Medical Journal Editors (ICMJE) made a seminal announcement in September 2004 that clinical trials that begin recruiting on or after July 1, 2005 would not be considered for publication unless they were included on a clinical trials registry (<a href="./references#CD003374-bbs2-0049" title="DeAngelisCD , DrazenJM , FrizelleFA , HaugC , HoeyJ , HortonR , et al. Is this clinical trial fully registered?—A statement from the International Committee of Medical Journal Editors. New England Journal of Medicine2005;352(23):2436‐8. ">De Angelis 2005</a>). Studies included in this review which began recruiting participants before July 1, 2005 and which did not have a trial registration or published protocol prespecifying study outcomes, were assumed to be at unclear risk of bias from selective reporting, unless additional evidence suggested otherwise. </p> <p>Six treatment‐comparisons from four studies were judged to be at low risk of bias from the selective reporting of outcomes (<a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a>; <a href="./references#CD003374-bbs2-0023" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 A</a>; <a href="./references#CD003374-bbs2-0024" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 B</a>; <a href="./references#CD003374-bbs2-0027" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 A</a>; <a href="./references#CD003374-bbs2-0028" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 B</a>). Each of these studies was included on a clinical trials registry and their prespecified outcomes either matched those in the trial reports or non‐matches were considered to be relatively minor. Three treatment‐comparisons were judged to be at high risk of bias from the selective reporting of outcomes. The first of these was <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> which specified TTP, TTF and toxicity as outcomes in the trial registration, but did not report on these outcomes in either of two conference abstracts (future publications may report in more detail and this 'risk of bias' assessment may change). The second was <a href="./references#CD003374-bbs2-0013" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first‐line treatment of metastatic triple‐negative breast cancer. Annals of Oncology2013;24(5):1219‐25. ">Fan 2012</a> which did not have a trial registration or published protocol and did not report the date that participants were first enrolled. However, given that <a href="./references#CD003374-bbs2-0013" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first‐line treatment of metastatic triple‐negative breast cancer. Annals of Oncology2013;24(5):1219‐25. ">Fan 2012</a> was first published in December 2012 and that there were only 53 study participants, it seemed highly likely that recruitment began after July 1, 2005. Consequently, there was a high expectation of trial registration which this study failed to undertake. The third of these was <a href="./references#CD003374-bbs2-0004" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple‐negative. European Journal of Cancer Supplements. 2009; Vol. 7, issue 3:18‐19. ">Bhattacharyya 2009</a> in which the abstract indicated that toxicity was recorded but no results were reported. In addition, for <a href="./references#CD003374-bbs2-0004" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple‐negative. European Journal of Cancer Supplements. 2009; Vol. 7, issue 3:18‐19. ">Bhattacharyya 2009</a>, there was no trial registration or published protocol containing prespecified outcomes. The date that participant recruitment began was not reported, but given that this was first published in September 2009, it seemed likely that recruitment began after July 1, 2005. As of April 2015, there had been no further results published other than those in the conference abstract. The remaining 19 treatment‐comparisons were judged to be at unclear risk of bias from the selective reporting of outcomes either because the trial was unregistered with recruitment starting before July 1, 2005 or the stated outcomes in the registry did not match those in the trial reports, but it was unclear if these non‐matches posed a high risk of bias. </p> <p>Egger's tests for funnel plot asymmetry did not identify evidence consistent with the presence of publication bias or small‐study effects, or both, for OS (P value = 0.98; <a href="#CD003374-fig-0003">Figure 3</a>), PFS/TTP (P value = 0.36) or OTRR (P value = 0.45). </p> <div class="figure" id="CD003374-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot 1: Overall survival (OS). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with extractable data for OS. The plot does not show asymmetry (Egger's test P value = 0.98)" data-id="CD003374-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot 1: Overall survival (OS). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with extractable data for OS. The plot does not show asymmetry (Egger's test P value = 0.98) </p> </div> </div> </div> </section> <section id="CD003374-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>Five treatment‐comparisons were judged to be at unclear risk of 'other bias' (<a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD003374-bbs2-0012" title="EisenT , SmithIE , DeBoerR , EllisPA . A randomised phase II trial of infusional 5‐FU and epirubicin with cyclophosphamide versus cisplatin in advanced breast cancer. Breast Cancer Research &amp; Treatment1997;46(1):94. EisenT , SmithIE , JohnstonS , EllisPA , PrendivilleJ , SeymourMT , et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. Journal of Clinical Oncology1998;16(4):1350‐7. ">Eisen 1998</a>; <a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a>; <a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a>; <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a>) for various reasons outlined in the <a href="./references#CD003374-sec-0112" title="">Characteristics of included studies</a> table. The remaining 23 treatment‐comparisons were judged to be at low risk of 'other bias'. </p> </section> </section> <section id="CD003374-sec-0070"> <h3 class="title" id="CD003374-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD003374-tbl-0001"><b>Summary of findings for the main comparison</b> Platinum‐containing regimens for women with metastatic breast cancer unselected for triple‐negative disease</a>; <a href="./full#CD003374-tbl-0002"><b>Summary of findings 2</b> Platinum‐containing regimens for women with metastatic triple‐negative breast cancer</a>; <a href="./full#CD003374-tbl-0003"><b>Summary of findings 3</b> Platinum‐containing regimens and toxicity profile</a> </p> <p>Refer to <a href="./full#CD003374-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD003374-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD003374-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD003374-sec-0071"> <h4 class="title">Overall survival (OS)</h4> <p>Twenty‐seven of the 28 included treatment‐comparisons assessed OS as an outcome; 19 provided sufficient OS data for pooling in meta‐analyses. From these 19 treatment‐comparisons, 2922 of 2956 randomised participants were analysed representing 99% of randomised participants in these treatment‐comparisons (and there were about 1868 deaths). There was no statistically significant difference in survival between platinum‐containing regimens or non‐platinum regimens with a HR of 0.98 (95% CI 0.89 to 1.07, P = 0.64) with some heterogeneity identified across trials (P = 0.04; I<sup>2</sup> = 39%) (<a href="./references#CD003374-fig-0007" title="">Analysis 1.1</a>; <a href="#CD003374-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD003374-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.1 Overall survival." data-id="CD003374-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.1 Overall survival. </p> </div> </div> </div> <p>Subgroup analysis showed a marginally significant survival benefit in favour of platinum‐containing regimens for three treatment‐comparisons assessing women with metastatic triple‐negative breast cancer (mTNBC) only (HR 0.75, 95% CI 0.57 to 1.00; P = 0.05; low‐quality evidence) (<a href="./references#CD003374-fig-0007" title="">Analysis 1.1</a>; <a href="#CD003374-fig-0004">Figure 4</a>). The difference between this pooled HR of 0.75 and that from 16 treatment‐comparisons assessing participants unselected for TNBC (HR 1.01, 95% CI 0.92 to 1.12; high‐quality evidence) was marginally significant (P = 0.05); heterogeneity was not large in either subgroup (P = 0.23, I<sup>2</sup> = 32% and P = 0.09, 34% respectively). The six other subgroup analyses showed no evidence of subgroup differences (P values ranged from P = 0.09 to P = 0.86; see <a href="./references#CD003374-fig-0010" title="">Analysis 2.1</a>; <a href="./references#CD003374-fig-0013" title="">Analysis 3.1</a>; <a href="./references#CD003374-fig-0022" title="">Analysis 4.1</a>; <a href="./references#CD003374-fig-0025" title="">Analysis 5.1</a>; <a href="./references#CD003374-fig-0028" title="">Analysis 6.1</a>; <a href="./references#CD003374-fig-0031" title="">Analysis 7.1</a>). </p> </section> <section id="CD003374-sec-0072"> <h4 class="title">Progression‐free survival/time to progression (PFS/TTP)</h4> <p>Twenty‐four of the 28 included treatment‐comparisons assessed PFS or TTP, or both, as an outcome; 16 provided sufficient data for pooling in meta‐analyses of the composite outcome of PFS/TTP. From these 16 treatment‐comparisons, 2136 out of 2162 (99%) randomised participants were analysed (and there were about 1772 events). There was a statistically significant difference in favour of platinum‐containing regimens (HR 0.85, 95% CI 0.78 to 0.93, P = 0.0002), although there was marked evidence of heterogeneity (P = 0.0004; I<sup>2</sup> = 63%) (<a href="./references#CD003374-fig-0008" title="">Analysis 1.2</a>; <a href="#CD003374-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD003374-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.2 Progression‐free survival/time to progression." data-id="CD003374-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.2 Progression‐free survival/time to progression. </p> </div> </div> </div> <p>Significant differences in the pooled HRs of subgroups were found in three of the seven subgroup analyses involving PFS/TTP. Specifically, there were significant differences in the pooled HRs for subgroups of treatment‐comparisons: </p> <p> <ul id="CD003374-list-0008"> <li> <p>assessing participants with mTNBC (HR 0.59, 95% CI 0.49 to 0.72; heterogeneity P = 0.07, I<sup>2</sup> = 62%; n = 3; low‐quality evidence) and unselected for mTNBC (HR 0.92, 95% CI 0.84 to 1.01; heterogeneity P = 0.08, I<sup>2</sup> = 38%; n = 13; moderate‐quality evidence) (P &lt; 0.0001 for subgroup difference) (<a href="./references#CD003374-fig-0008" title="">Analysis 1.2</a>; <a href="#CD003374-fig-0005">Figure 5</a>). </p> </li> </ul> <ul id="CD003374-list-0009"> <li> <p>with &gt; 80% of participants receiving first‐line therapy (HR 0.93, 95% CI 0.83 to 1.03; heterogeneity P = 0.003, I<sup>2</sup> = 63%; n = 11) and &gt; 20% of participants receiving second‐ or third‐line therapy (HR 0.75, 95% CI 0.65 to 0.86; heterogeneity P = 0.12, I<sup>2</sup> = 45%; n = 5) (P = 0.01 for subgroup difference) (<a href="./references#CD003374-fig-0023" title="">Analysis 4.2</a>). </p> </li> </ul> <ul id="CD003374-list-0010"> <li> <p>with no anthracycline in the platinum or non‐platinum regimens (HR 0.80, 95% CI 0.73 to 0.88; heterogeneity P = 0.001, I<sup>2</sup> = 65%; n = 11), an anthracycline in both the platinum and non‐platinum regimens (HR 1.05, 95% CI 0.86 to 1.27; heterogeneity P = 0.35, I<sup>2</sup> = 8%; n = 4) and an anthracycline in the platinum regimen only (HR 1.23, 95% CI 0.75 to 2.03; n = 1) (P = 0.02 for subgroup difference) (<a href="./references#CD003374-fig-0026" title="">Analysis 5.2</a>). </p> </li> </ul> </p> <p>The four other subgroup analyses showed no evidence of subgroup differences (P values ranged from P = 0.34 to P = 0.88; see <a href="./references#CD003374-fig-0014" title="">Analysis 3.2</a>; <a href="./references#CD003374-fig-0029" title="">Analysis 6.2</a>; <a href="./references#CD003374-fig-0032" title="">Analysis 7.2</a>; <a href="./references#CD003374-fig-0035" title="">Analysis 8.2</a>). </p> </section> <section id="CD003374-sec-0073"> <h4 class="title">Time to treatment failure (TTF)</h4> <p>Three of the 28 included treatment‐comparisons assessed TTF as an outcome but only one provided sufficient data for extraction (<a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004:</a> HR 0.88, 95% CI 0.69 to 1.13). </p> </section> <section id="CD003374-sec-0074"> <h4 class="title">Objective Tumour Response Rate (OTRR) — assessable participants</h4> <p>All 28 included treatment‐comparisons assessed OTRR as an outcome and provided sufficient data for extraction. From the 28 treatment‐comparisons, 4130 out of 4475 (92%) randomised participants were assessable for tumour response (and 2017 had a complete or partial response). There was a statistically significant difference in OTRRs in favour of platinum‐containing regimens (RR 1.15, 95% CI 1.08 to 1.22, P &lt; 0.0001), but there was also considerable evidence of heterogeneity (P &lt; 0.0001; I<sup>2</sup> = 64%) (<a href="./references#CD003374-fig-0009" title="">Analysis 1.3</a>; <a href="#CD003374-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD003374-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.3 Objective tumour response rate (assessable participants)." data-id="CD003374-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.3 Objective tumour response rate (assessable participants). </p> </div> </div> </div> <p>Significant differences in the pooled RRs of subgroups were found in five of the seven OTRR subgroup analyses. Specifically, there were significant differences in the pooled RRs for subgroups of treatment‐comparisons: </p> <p> <ul id="CD003374-list-0011"> <li> <p>assessing participants with mTNBC (RR 1.33, 95% CI 1.13 to 1.56; heterogeneity P = 0.0010, I<sup>2</sup> = 78%; n = 5; low‐quality evidence) and unselected for mTNBC (RR 1.11, 95% CI 1.04 to 1.19; heterogeneity P = 0.0002, I<sup>2</sup> = 58%; n = 23; low‐quality evidence) (P = 0.05 for subgroup difference) (<a href="./references#CD003374-fig-0009" title="">Analysis 1.3</a>; <a href="#CD003374-fig-0006">Figure 6</a>). </p> </li> </ul> <ul id="CD003374-list-0012"> <li> <p>comparing 'regimen A + platinum vs regimen A' (RR 1.10, 95% CI 1.01 to 1.21; heterogeneity P = 0.009, I<sup>2</sup> = 61%; n = 9), 'regimen A + platinum vs regimen B' (RR 1.22, 95% CI 1.12 to 1.33; heterogeneity P = 0.0002, I<sup>2</sup> = 63%; n = 18) and 'single agent platinum vs regimen C' (RR 0.88, 95% CI 0.66 to 1.17; n = 1) (P = 0.05 for subgroup difference) (<a href="./references#CD003374-fig-0012" title="">Analysis 2.3</a>). </p> </li> </ul> <ul id="CD003374-list-0013"> <li> <p>using cisplatin (RR 1.35, 95% CI 1.24 to 1.46; heterogeneity P = 0.006, I<sup>2</sup> = 53%; n = 17), carboplatin (RR 0.94, 95% CI 0.86 to 1.04; heterogeneity P = 0.10, I<sup>2</sup> = 38%; n = 10) and oxaliplatin (RR 0.85, 95% CI 0.48 to 1.52; n = 1) as the platinum agent in the platinum regimen (P &lt; 0.0001 for subgroup difference) (<a href="./references#CD003374-fig-0015" title="">Analysis 3.3</a>). </p> </li> </ul> <ul id="CD003374-list-0014"> <li> <p>with no anthracycline in their platinum or non‐platinum regimens (RR 1.10, 95% CI 1.02 to 1.20; heterogeneity P &lt; 0.0001, I<sup>2</sup> = 65%; n = 18), an anthracycline in both the platinum and non‐platinum regimens (RR 1.09, 95% CI 0.97 to 1.22; heterogeneity P = 0.12, I<sup>2</sup> = 42%; n = 6) and an anthracycline in the platinum regimen only (RR 1.49, 95% CI 1.28 to 1.74; heterogeneity P = 0.38, I<sup>2</sup> = 2%; n = 4) (P = 0.002 for subgroup difference) (<a href="./references#CD003374-fig-0027" title="">Analysis 5.3</a>). </p> </li> </ul> <ul id="CD003374-list-0015"> <li> <p>with no taxane in the platinum or non‐platinum regimens (RR 1.25, 95% CI 1.15 to 1.36; heterogeneity P = 0.009, I<sup>2</sup> = 51%; n = 17), a taxane in both platinum and non‐platinum regimens (RR 1.01, 95% CI 0.90 to 1.12; heterogeneity P = 0.002, I<sup>2</sup> = 74%; n = 6) and a taxane in the non‐platinum regimen only (RR 1.11, 95% CI 0.94 to 1.30; heterogeneity P = 0.02, I<sup>2</sup> = 67%; n = 5) (P = 0.007 for subgroup difference) (<a href="./references#CD003374-fig-0030" title="">Analysis 6.3</a>). </p> </li> </ul> </p> <p>The two other subgroup analyses showed no evidence of subgroup differences (P = 0.55, <a href="./references#CD003374-fig-0024" title="">Analysis 4.3</a>; and P = 0.94, <a href="./references#CD003374-fig-0033" title="">Analysis 7.3</a>). </p> </section> <section id="CD003374-sec-0075"> <h4 class="title"><i>Toxicity — safety populations</i> </h4> <section id="CD003374-sec-0076"> <h5 class="title"><i>Treatment‐related death</i> </h5> <p>Fifteen of the 28 included treatment‐comparisons assessed treatment‐related death and provided sufficient data for extraction. Of these 15 treatment‐comparisons, five had non‐estimable RRs due to no treatment‐related deaths and, consequently, did not contribute to the pooled estimates. For the 10 remaining treatment‐comparisons, 1688 out of 1759 (96%) randomised women were included in the safety populations, with 32 treatment‐related deaths. There was no significant difference between platinum and non‐platinum regimens in terms of treatment‐related death but the confidence interval was wide (RR 1.42, 95% CI 0.73 to 2.76; <a href="./references#CD003374-fig-0016" title="">Analysis 3.4</a>). There was no evidence of heterogeneity (P = 0.94, I<sup>2</sup> = 0%). </p> <p>No significant differences in pooled RRs were found according to the type of platinum agent used (P = 0.61). </p> </section> <section id="CD003374-sec-0077"> <h5 class="title"><i>Nausea/vomiting</i> </h5> <p>Twenty‐one of the 28 included treatment‐comparisons assessed grade 3 and 4 nausea/vomiting with sufficient data for extraction. One treatment‐comparison had a non‐estimable RR due to there being no grade 3 or 4 cases. For the 20 remaining treatment‐comparisons, 3101 out of 3192 (97%) randomised women were included in the safety populations with 364 cases of grade 3 or 4 nausea/vomiting. Risk of grade 3 or 4 nausea/vomiting was significantly higher among women receiving platinum‐containing regimens (RR 2.07, 95% CI 1.69 to 2.54, P &lt; 0.0001) but there was also considerable evidence of heterogeneity (P = 0.0003, I<sup>2</sup> = 60%) (<a href="./references#CD003374-fig-0017" title="">Analysis 3.5</a>). </p> <p>Subgroup analysis indicated that the increased risk of grade 3 or 4 nausea/vomiting for platinum recipients (compared to non‐platinum recipients) was primarily driven by cisplatin rather than carboplatin use. Specifically, there was a significant difference in the pooled RR for treatment‐comparisons using cisplatin (RR 2.65, 95% CI 2.10 to 3.34; n = 14; moderate‐quality evidence) rather than carboplatin (RR 0.77, 95% CI 0.47 to 1.26; n = 6; moderate‐quality evidence) in their platinum‐containing regimens (P &lt; 0.0001 for subgroup difference). There was evidence of heterogeneity in the cisplatin (P = 0.008, I<sup>2</sup> = 54%) but not the carboplatin (P = 0.30, I<sup>2</sup> = 17%) subgroup. </p> </section> <section id="CD003374-sec-0078"> <h5 class="title"><i>Nephrotoxicity</i> </h5> <p>Five of the 28 included treatment‐comparisons assessed grade 3 and 4 nephrotoxicity and reported sufficient data for extraction. One treatment‐comparison had a non‐estimable RR due to there being no grade 3 or 4 cases. For the four remaining treatment‐comparisons, 557 out of 571 (98%) randomised women were included in the safety populations, with 11 cases of grade 3 or 4 nephrotoxicity. Risk of grade 3 or 4 nephrotoxicity was more than three‐fold higher among women receiving platinum‐containing regimens, but this increase in risk was not significant (RR 3.06, 95% CI 0.86 to 10.84, P = 0.08) (<a href="./references#CD003374-fig-0018" title="">Analysis 3.6</a>). There was no evidence of heterogeneity (P = 0.92, I<sup>2</sup> = 0%). </p> <p>No significant differences in pooled RRs were found according to the type of platinum agent used (P = 0.65). </p> </section> <section id="CD003374-sec-0079"> <h5 class="title"><i>Anaemia</i> </h5> <p>Twenty of the 28 included treatment‐comparisons assessed grade 3 and 4 anaemia with sufficient data for extraction. One treatment‐comparison had a non‐estimable RR due to there being no grade 3 or 4 anaemia cases. For the 19 remaining treatment‐comparisons, 3032 out of 3107 (98%) randomised women were included in the safety populations, with 176 cases of grade 3 or 4 anaemia. Risk of grade 3 or 4 anaemia was significantly higher among women receiving platinum‐containing regimens (RR 2.61, 95% CI 1.90 to 3.58, P &lt; 0.0001) (<a href="./references#CD003374-fig-0019" title="">Analysis 3.7</a>). There was no evidence of heterogeneity (P = 0.41, I<sup>2</sup> = 4%). </p> <p>Subgroup analysis indicated that the increased risk of grade 3 or 4 anaemia for platinum recipients (compared to non‐platinum recipients) was worse for cisplatin recipients compared to carboplatin recipients. Specifically, there was a significant difference between the pooled RRs for treatment‐comparisons using cisplatin (RR 3.72, 95% CI 2.36 to 5.88; n =12; high‐quality evidence) rather than carboplatin (RR 1.72, 95% CI 1.10 to 2.70; n = 7; high‐quality evidence) in their platinum‐containing regimens (P = 0.02 for subgroup difference). There was no evidence of heterogeneity in the cisplatin or carboplatin subgroups (P = 0.50 and P = 0.67, respectively; I<sup>2</sup> = 0% and I<sup>2</sup> = 0%, respectively). </p> </section> <section id="CD003374-sec-0080"> <h5 class="title"><i>Hair Loss</i> </h5> <p>Twelve of the 28 included treatment‐comparisons assessed grade 3 and 4 hair loss and reported sufficient data for extraction. Three treatment‐comparisons had a non‐estimable RR due to there being no grade 3 or 4 cases. For the nine remaining treatment‐comparisons, 1080 out of 1089 (99%) randomised women were included in the safety populations, with 469 cases of grade 3 or 4 hair loss. Risk of grade 3 or 4 hair loss was significantly higher among women receiving platinum‐containing regimens (RR 1.41, 95% CI 1.26 to 1.58, P &lt; 0.0001; high‐quality evidence) (<a href="./references#CD003374-fig-0020" title="">Analysis 3.8</a>). There was some indication of heterogeneity (P = 0.10, I<sup>2</sup> = 40%). </p> <p>No significant differences in pooled RRs were found according to the type of platinum agent used (P = 0.23). </p> </section> <section id="CD003374-sec-0081"> <h5 class="title"><i>Leukopenia</i> </h5> <p>Twenty‐two of the 28 included treatment‐comparisons assessed grade 3 and 4 leukopenia and reported sufficient data for extraction. One treatment‐comparison had a non‐estimable RR due to there being no grade 3 or 4 cases of leukopenia. For the 21 remaining treatment‐comparisons, 3123 out of 3222 (97%) randomised women were included in the safety populations, with 628 cases of grade 3 or 4 leukopenia. Risk of grade 3 or 4 leukopenia was significantly higher among women receiving platinum‐containing regimens (RR 1.38, 95% CI 1.21 to 1.57, P &lt; 0.0001; moderate‐quality evidence) but with evidence of heterogeneity (P = 0.0002, I<sup>2</sup> = 62%) (<a href="./references#CD003374-fig-0021" title="">Analysis 3.9</a>). </p> <p>No significant differences in pooled RRs were found according to the type of platinum agent used (P = 0.21). </p> </section> </section> <section id="CD003374-sec-0082"> <h4 class="title">Quality of life</h4> <p>Three studies reported treatment effects on quality of life; <a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a> (EORTC QLQ‐C30), Fountzilas 2009 (<a href="./references#CD003374-bbs2-0015" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 A</a>; <a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a>) (EUROQOL EQ5D and EQ VAS) and <a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a> (EORTC QLQ‐C30). However, quality of life results could not be pooled in a meta‐analysis because only one quality of life domain was common to two treatment‐comparisons (the EORTC QLQ‐C30 'global' domain reported by <a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a> and <a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a>) and only one reported sufficient data for extraction (<a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a>) . </p> <p><a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a> found paclitaxel/carboplatin was associated with an improvement both in the emotional functioning scale and in sleep disturbance symptoms compared with paclitaxel/epirubicin, but did not find significant group differences in any other quality of life domains assessed (physical role, cognitive, social, global quality of life, fatigue, nausea and vomiting, pain, dyspnoea, appetite loss, constipation, diarrhoea, financial impact). Fountzilas 2009 (<a href="./references#CD003374-bbs2-0015" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 A</a>; <a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a>) found that changes in quality across time did not differ significantly between groups for the domains reported (EQ5D index and EQ VAS score). <a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a> found that pemetrexed/carboplatin participants had significantly greater deterioration in global health status scores (follow‐up minus baseline scores) than vinorelbine/gemcitabine participants, but there was no significance difference in body image scores between groups. </p> </section> <section id="CD003374-sec-0083"> <h4 class="title"><i>Sensitivity analyses</i> </h4> <p>Restricting the OTRR meta‐analysis to the 19 treatment‐comparisons with extractable data on OS had little impact on the pooled RR estimate (RR = 1.15 and RR = 1.13 in the original and sensitivity analyses, respectively). Restricting the OS and PFS/TTP meta‐analyses to the 12 treatment‐comparisons with extractable data on both OS and OS and PFS/TTP lowered the pooled HR estimate from HR = 0.98 to HR = 0.92 for OS, and from 0.85 to 0.80 for PFS/TTP. This represented a 6% reduction in the HR estimates for both OS and PFS/TTP and suggested that the relative difference between OS and PFS/TTP results was unlikely to be due to the different treatment‐comparisons available for the meta‐analysis of each outcome. </p> <p>Stratifying PFS/TTP estimates according to whether the outcome was PFS or TTP suggested that platinum chemotherapy was more beneficial in terms of TTP than PFS, although the difference was not statistically significant (P = 0.06). Repeating <a href="./references#CD003374-fig-0007" title="">Analysis 1.1</a>, and <a href="./references#CD003374-fig-0008" title="">Analysis 1.2</a> using random‐effects methods did not appreciably change the point estimates for OS or PFS/TTP, but did produce slightly wider confidence intervals (<a href="./references#CD003374-fig-0038" title="">Analysis 10.1</a>; <a href="./references#CD003374-fig-0039" title="">Analysis 10.2</a>). Repeating <a href="./references#CD003374-fig-0009" title="">Analysis 1.3</a> using a random‐effects model did not appreciably change the OTRR point estimate for participants unselected for mTNBC, but did increase the point estimate for mTNBC participants (from 1.33 to 1.60). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003374-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003374-sec-0084"></div> <section id="CD003374-sec-0085"> <h3 class="title" id="CD003374-sec-0085">Summary of main results</h3> <p>In this review update and consistent with the findings of the original review, our results did not show an OS benefit from platinum‐containing regimens compared to non‐platinum regimens for women with metastatic breast cancer 'in general' (i.e. without regard to subgroups). The confidence limits for the OS pooled HR estimate suggested that platinum‐containing regimens were unlikely to confer more than a 11% reduction in the risk of death and might increase the risk by up to 7%. The lack of an OS benefit for platinum‐containing regimens was somewhat at odds with the significant PFS/TTP and OTRR benefits observed in this review. Compared to women receiving non‐platinum regimens, those receiving platinum‐containing regimens had a 15% lower rate of progression or death (as measured by PFS/TTP) and a 15% higher rate of complete or partial tumour response. Sensitivity analyses indicated that the discrepancies between the OS and OTRR findings, and between the OS and PFS/TTP findings, were unlikely to be due to the different sets of treatment‐comparisons used in the various meta‐analyses of OS, PFS/TTP and OTRR. Rather, these discrepancies seemed more likely to be related to PFS/TTP and OTRR being somewhat poor surrogate outcomes for OS in metastatic breast cancer research (<a href="./references#CD003374-bbs2-0045" title="BurzykowskiT , BuyseM , Piccart‐GebhartMJ , SledgeG , CarmichaelJ , LückHJ , et al. Evaluation of tumor response, disease control, progression‐free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology2008;26(12):1987‐92. ">Burzykowski 2008</a>), and perhaps also related to general difficulties in measuring tumour response. Given that OS is generally regarded as the outcome of choice for assessing treatment efficacy in metastatic breast cancer research (<a href="./references#CD003374-bbs2-0045" title="BurzykowskiT , BuyseM , Piccart‐GebhartMJ , SledgeG , CarmichaelJ , LückHJ , et al. Evaluation of tumor response, disease control, progression‐free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology2008;26(12):1987‐92. ">Burzykowski 2008</a>) and given that this review now has a sufficient number of included studies to estimate the effects of treatments on OS with relatively high precision, we think that considerably more weight should be given to the OS results than the PFS/TTP or OTRR results. </p> <p>In the absence of subgroup analyses, heterogeneity of effect estimates was observed for PFS/TTP, OTRR and, to a lesser degree, OS. With regards to OS and PFS/TTP, heterogeneity was explained to a large extent by the triple‐negative status of study participants. More specifically for OS, data from three treatment‐comparisons assessing mTNBC participants showed a 25% reduction in the risk of death for recipients of platinum‐containing regimens compared to recipients of non‐platinum regimens (P = 0.05). In absolute terms, this 25% risk ratio reduction corresponded to about 93 fewer deaths at one year after metastatic diagnosis for every 1000 mTNBC participants who received platinum‐containing chemotherapy, and about 105 fewer deaths at two years (<a href="./full#CD003374-tbl-0002">summary of findings Table 2</a>). In contrast, data from 16 treatment‐comparisons, assessing participants unselected for TNBC, showed similar risks of death among platinum and non‐platinum recipients (HR = 1.01). In relation to PFS/TTP, platinum‐containing regimens reduced the risk of death or progression, or both, by about 41% for mTNBC participants (P &lt; 0.0001) but only by about 8% for participants unselected for mTNBC (P = 0.10). The difference between the pooled effect estimates of the mTNBC and 'unselected for mTNBC' subgroups was significant for PFS/TTP (P &lt; 0.0001) and on the margins of statistical significance for OS (P = 0.05) and OTRR (P = 0.05). </p> <p>While we also found a number of other statistically significant subgroup differences for OTRR and PFS/TTP (see <a href="#CD003374-sec-0070">Effects of interventions</a>), it is difficult to judge the importance or reliability of these findings, given that similar differences were not observed in relation to OS. </p> <p>Assessments of toxicity showed that women receiving platinum‐containing regimens experienced higher rates of grade 3 and 4 nausea/vomiting, anaemia, leukopenia and hair loss than women receiving non‐platinum regimens. Subgroup analysis indicated that the higher rate of grade 3 and 4 nausea/vomiting was associated with cisplatin but not carboplatin use, and the increased risk of grade 3 and 4 anaemia was higher for cisplatin recipients than for carboplatin recipients. </p> </section> <section id="CD003374-sec-0086"> <h3 class="title" id="CD003374-sec-0086">Overall completeness and applicability of evidence</h3> <p>This review now includes data from 24 studies relating to 28 treatment‐comparisons, with publications years ranging from 1984 to 2014. Of the 28 treatment‐comparisons,19 (68%) and 16 (57%) provided sufficient time‐to‐event data to be included in OS and PFS/TTP meta‐analyses, respectively. All 28 treatment‐comparisons provided OTRR data that could be included in meta‐analyses. A majority of treatment‐comparisons had sufficient data on treatment‐related death (n =15; 54%), nausea/vomiting (n =21; 75%), anaemia (n =20; 71%) and leukopenia (n =22; 79%) for inclusion in meta‐analyses. Five (18%) and 12 (43%) treatment‐comparisons had sufficient data on nephrotoxicity and hair loss for pooling, respectively. The evidence relating to treatment effects on quality of life remained almost wholly incomplete, with only three studies reporting quality of life results that could not be pooled in meta‐analysis. </p> <p>Although data for the most important outcome (OS) was extractable for 68% of treatment‐comparisons, the evidence would clearly be more complete if OS data were extractable for all 28 treatment‐comparisons. Nonetheless, it is somewhat reassuring that sensitivity analyses restricting the OTRR meta‐analysis to the 19 treatment‐comparisons with extractable OS data did not appreciably change the OTRR pooled estimate of effect (RR=1.15 and RR=1.13 in the original and sensitivity analyses, respectively). This provides some evidence that the 'overall' pooled effect estimate for OS was unlikely to have changed substantively if OS data were extractable for all 28 treatment‐comparisons. It is important to note, however, that although the 'overall' pooled estimate of effect for OS appeared robust to the missing treatment‐comparisons, this may not be the case for smaller subgroups. For example, our finding of a significant OS benefit for mTNBC participants receiving platinum‐containing regimens ― based on data from only three treatment‐comparisons ― may have been different if we were able to include OS data from <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> in the meta‐analysis. In this relatively large treatment‐comparison of mainly mTNBC participants, median OS times were similar in the platinum and non‐platinum groups. </p> <p>The evidence in this review appeared to be generally applicable to the current practice of the treatment of metastatic breast cancer for a number of reasons. First, the platinum and non‐platinum regimens used in the included trials contained most chemotherapy drugs currently used in clinical practice to treat metastatic breast cancer, including cyclophosphamide, methotrexate, fluorouracil (CMF), trastuzumab and various anthracyclines and taxanes. Second, the review included trials of women receiving first‐line treatment and women receiving treatment after failure of previous anthracycline or taxane regimens. Third, the review was well populated with trials using the two most commonly used platinum agents for treating metastatic breast cancer ― carboplatin and cisplatin. While the review had only one trial using oxaliplatin as the platinum agent, oxaliplatin is not widely used in clinical practice for treating breast cancers. Fourth, this review update is the first to use meta‐analysis to synthesise the evidence on an issue of considerable interest and importance to clinical practice; namely, whether platinum‐based chemotherapies improved survival outcomes for mTNBC participants. </p> </section> <section id="CD003374-sec-0087"> <h3 class="title" id="CD003374-sec-0087">Quality of the evidence</h3> <p>Quality of evidence ratings relating to OS, PFS/TTP and OTRR effect estimates were graded separately for the subgroups of treatment‐comparisons with women unselected for mTNBC (<a href="./full#CD003374-tbl-0001">summary of findings Table for the main comparison</a>) and with mTNBC (<a href="./full#CD003374-tbl-0002">summary of findings Table 2</a>). We identified no problems using the GRADE assessment criteria in relation to the OS effect estimate for the 'unselected' subgroup; hence, the quality of the evidence for this estimate was rated 'high'. For the 'mTNBC' subgroup, the quality of the evidence rating for the OS effect estimate was downgraded two levels to 'low' for 'imprecision' (because the confidence interval for the pooled estimate was wide and close to the null) and for 'suspected publication bias' (because of the absence of <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> from the OS meta‐analysis). The quality of the evidence ratings for PFS/TTP and OTRR effect estimates ranged from 'low' to 'moderate' across the 'unselected' and 'mTNBC' subgroups for reasons including 'indirectness', 'imprecision' , 'inconsistency' and 'suspected publication bias' (see <a href="./full#CD003374-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD003374-tbl-0002">summary of findings Table 2</a> for details). </p> <p>Treatment effect estimates for four key toxicity outcomes were graded for quality of evidence (<a href="./full#CD003374-tbl-0003">summary of findings Table 3</a>). Gradings were stratified by 'type of platinum agent' (cisplatin or carboplatin) for nausea/vomiting and anaemia and not stratified for hair loss and leukopenia (because hair loss and leukopenia were not significantly related to 'type of platinum agent'). The quality of the evidence ratings were 'high' for hair loss and for anaemia (both cisplatin and carboplatin subgroups), and downgraded one level to 'moderate' for nausea/vomiting (both cisplatin and carboplatin subgroups) and leukopenia due to either 'imprecision' or 'inconsistency' (see <a href="./full#CD003374-tbl-0003">summary of findings Table 3</a> for details). </p> </section> <section id="CD003374-sec-0088"> <h3 class="title" id="CD003374-sec-0088">Potential biases in the review process</h3> <p>Although it is possible that we may not have identified every eligible study with published results, study protocol or clinical trial registration, this seemed unlikely given our highly sensitive search strategies, including access to the Cochrane Breast Cancer Specialised Register maintained by the Cochrane Breast Cancer Group. A related but more insidious problem, however, was the risk of reporting bias arising from completed studies that never published their (largely) negative findings. While non‐publication of negative findings probably has occurred less frequently in recent years (due to increasing pressures to preregister clinical trials and publish results within reasonable time‐frames), many systematic reviews remain vulnerable to historical reporting bias. In this review, many of the included studies were conducted in an era when non‐publication of negative findings was more likely, but it seemed unlikely that this would have substantively affected our OS main finding, given that this finding was itself negative. </p> </section> <section id="CD003374-sec-0089"> <h3 class="title" id="CD003374-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD003374-bbs2-0064" title="PetrelliF , BarniS , BregniG , DeBraudF , DiCosimoS . Platinum salts in advanced breast cancer: a systematic review and meta‐analysis of randomized clinical trials. Breast Cancer Research and Treatment2016;160(3):425‐37. ">Petrelli 2016</a> recently published a systematic review and meta‐analysis of randomised trials to assess the efficacy and safety of therapy with platinum salts in participants with locally advanced or metastatic breast cancer. In their review, Petrelli reported overall pooled effect estimates similar to our estimates in terms of OS (HR = 0.91 vs HR = 0.98, respectively), PFS/TTP (HR = 0.84 vs HR = 0.85, respectively) and OTRR (odds ratio = 1.27 vs odds ratio = 1.33, respectively after recalculating our relative risk estimate into an odds ratio). It is important to note, however, that while the overall results of the two systematic reviews are similar, <a href="./references#CD003374-bbs2-0064" title="PetrelliF , BarniS , BregniG , DeBraudF , DiCosimoS . Platinum salts in advanced breast cancer: a systematic review and meta‐analysis of randomized clinical trials. Breast Cancer Research and Treatment2016;160(3):425‐37. ">Petrelli 2016</a> included studies with 100% locally advanced participants whereas our review excluded studies with more than 20% of participants having isolated locoregional recurrence. In addition, our review extended the work of Petrelli through the inclusion of multiple additional subgroup analyses. </p> <p>To our knowledge, there has been only one other systematic review of randomised trials comparing the effects of platinum and non‐platinum‐containing regimens among participants with mTNBC (<a href="./references#CD003374-bbs2-0055" title="GuanX , MaF , FanY , ZhuW , HongR , XuB . Platinum‐based chemotherapy in triple‐negative breast cancer: a systematic review and meta‐analysis of randomized‐controlled trials. Anti‐cancer Drugs2015;26(8):894‐901. ">Guan 2015</a>). That review, however, only performed meta‐analyses of tumour response rates and not time‐to‐event outcomes. The OTRR meta‐analysis in <a href="./references#CD003374-bbs2-0055" title="GuanX , MaF , FanY , ZhuW , HongR , XuB . Platinum‐based chemotherapy in triple‐negative breast cancer: a systematic review and meta‐analysis of randomized‐controlled trials. Anti‐cancer Drugs2015;26(8):894‐901. ">Guan 2015</a> was comprised of three of the five mTNBC treatment‐comparisons included in the current review (<a href="./references#CD003374-bbs2-0004" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple‐negative. European Journal of Cancer Supplements. 2009; Vol. 7, issue 3:18‐19. ">Bhattacharyya 2009</a>; <a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a>; <a href="./references#CD003374-bbs2-0013" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first‐line treatment of metastatic triple‐negative breast cancer. Annals of Oncology2013;24(5):1219‐25. ">Fan 2012</a>); the additional inclusion of <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> and <a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a> in the current review resulted in a pooled OTRR estimate of effect (RR 1.33, 95% CI 1.13 to 1.56), significantly lower than that of <a href="./references#CD003374-bbs2-0055" title="GuanX , MaF , FanY , ZhuW , HongR , XuB . Platinum‐based chemotherapy in triple‐negative breast cancer: a systematic review and meta‐analysis of randomized‐controlled trials. Anti‐cancer Drugs2015;26(8):894‐901. ">Guan 2015</a> (RR 2.42, 95% CI 1.66 to 3.53). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003374-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Review update 2016: study flow diagram." data-id="CD003374-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Review update 2016: study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003374-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot 1: Overall survival (OS). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with extractable data for OS. The plot does not show asymmetry (Egger's test P value = 0.98)" data-id="CD003374-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot 1: Overall survival (OS). Assessing publication bias and/or small‐study effects. Plot includes all treatment‐comparisons with extractable data for OS. The plot does not show asymmetry (Egger's test P value = 0.98) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.1 Overall survival." data-id="CD003374-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.2 Progression‐free survival/time to progression." data-id="CD003374-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.2 Progression‐free survival/time to progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.3 Objective tumour response rate (assessable participants)." data-id="CD003374-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), outcome: 1.3 Objective tumour response rate (assessable participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), Outcome 1 Overall survival." data-id="CD003374-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), Outcome 2 Progression‐free survival/time to progression." data-id="CD003374-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), Outcome 2 Progression‐free survival/time to progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), Outcome 3 Objective tumour response rate (assessable participants)." data-id="CD003374-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC), Outcome 3 Objective tumour response rate (assessable participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Platinum vs non‐platinum regimens (subgroup analysis 2: by type of regimen comparison), Outcome 1 Overall survival." data-id="CD003374-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Platinum vs non‐platinum regimens (subgroup analysis 2: by type of regimen comparison), Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Platinum vs non‐platinum regimens (subgroup analysis 2: by type of regimen comparison), Outcome 2 Progression‐free survival / time to progression." data-id="CD003374-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Platinum vs non‐platinum regimens (subgroup analysis 2: by type of regimen comparison), Outcome 2 Progression‐free survival / time to progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Platinum vs non‐platinum regimens (subgroup analysis 2: by type of regimen comparison), Outcome 3 Objective tumour response rate (assessable participants)." data-id="CD003374-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Platinum vs non‐platinum regimens (subgroup analysis 2: by type of regimen comparison), Outcome 3 Objective tumour response rate (assessable participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 1 Overall survival." data-id="CD003374-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 2 Progression‐free survival/time to progression." data-id="CD003374-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 2 Progression‐free survival/time to progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 3 Objective tumour response rate (assessable participants)." data-id="CD003374-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 3 Objective tumour response rate (assessable participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 4 Treatment‐related death (safety population)." data-id="CD003374-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 4 Treatment‐related death (safety population). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 5 Nausea/vomiting (safety population)." data-id="CD003374-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 5 Nausea/vomiting (safety population). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 6 Nephrotoxicity (safety population)." data-id="CD003374-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 6 Nephrotoxicity (safety population). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 7 Anaemia (safety population)." data-id="CD003374-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 7 Anaemia (safety population). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 8 Hair loss (safety population)." data-id="CD003374-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 8 Hair loss (safety population). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 9 Leukopenia (safety population)." data-id="CD003374-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm), Outcome 9 Leukopenia (safety population). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Platinum vs non‐platinum regimens (subgroup analysis 4: by first‐line therapy), Outcome 1 Overall survival." data-id="CD003374-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Platinum vs non‐platinum regimens (subgroup analysis 4: by first‐line therapy), Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Platinum vs non‐platinum regimens (subgroup analysis 4: by first‐line therapy), Outcome 2 Progression‐free survival/time to progression." data-id="CD003374-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Platinum vs non‐platinum regimens (subgroup analysis 4: by first‐line therapy), Outcome 2 Progression‐free survival/time to progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Platinum vs non‐platinum regimens (subgroup analysis 4: by first‐line therapy), Outcome 3 Objective tumour response rate (assessable participants)." data-id="CD003374-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Platinum vs non‐platinum regimens (subgroup analysis 4: by first‐line therapy), Outcome 3 Objective tumour response rate (assessable participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Platinum vs non‐platinum regimens (subgroup analysis 5 by anthracycline in regimens), Outcome 1 Overall survival." data-id="CD003374-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Platinum vs non‐platinum regimens (subgroup analysis 5 by anthracycline in regimens), Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Platinum vs non‐platinum regimens (subgroup analysis 5 by anthracycline in regimens), Outcome 2 Progression‐free survival/time to progression." data-id="CD003374-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Platinum vs non‐platinum regimens (subgroup analysis 5 by anthracycline in regimens), Outcome 2 Progression‐free survival/time to progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Platinum vs non‐platinum regimens (subgroup analysis 5 by anthracycline in regimens), Outcome 3 Objective tumour response rate (assessable participants)." data-id="CD003374-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Platinum vs non‐platinum regimens (subgroup analysis 5 by anthracycline in regimens), Outcome 3 Objective tumour response rate (assessable participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Platinum vs non‐platinum regimens (subgroup analysis 6: by taxane in regimens), Outcome 1 Overall survival." data-id="CD003374-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Platinum vs non‐platinum regimens (subgroup analysis 6: by taxane in regimens), Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Platinum vs non‐platinum regimens (subgroup analysis 6: by taxane in regimens), Outcome 2 Progression‐free survival / time to progression." data-id="CD003374-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Platinum vs non‐platinum regimens (subgroup analysis 6: by taxane in regimens), Outcome 2 Progression‐free survival / time to progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Platinum vs non‐platinum regimens (subgroup analysis 6: by taxane in regimens), Outcome 3 Objective tumour response rate (assessable participants)." data-id="CD003374-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Platinum vs non‐platinum regimens (subgroup analysis 6: by taxane in regimens), Outcome 3 Objective tumour response rate (assessable participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Platinum vs non‐platinum regimens (subgroup analysis 7: by trastuzumab in regimens), Outcome 1 Overall survival." data-id="CD003374-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Platinum vs non‐platinum regimens (subgroup analysis 7: by trastuzumab in regimens), Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Platinum vs non‐platinum regimens (subgroup analysis 7: by trastuzumab in regimens), Outcome 2 Progression‐free survival/time to progression." data-id="CD003374-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Platinum vs non‐platinum regimens (subgroup analysis 7: by trastuzumab in regimens), Outcome 2 Progression‐free survival/time to progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Platinum vs non‐platinum regimens (subgroup analysis 7: by trastuzumab in regimens), Outcome 3 Objective tumour response rate (assessable participants)." data-id="CD003374-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Platinum vs non‐platinum regimens (subgroup analysis 7: by trastuzumab in regimens), Outcome 3 Objective tumour response rate (assessable participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Platinum vs non‐platinum regimens (sensitivity analysis 1: excluding selected treatment‐comparisons), Outcome 1 Overall survival (restricted to the 12 treatment‐comparisons common to OS and PFS/TTP meta‐analyses)." data-id="CD003374-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Platinum vs non‐platinum regimens (sensitivity analysis 1: excluding selected treatment‐comparisons), Outcome 1 Overall survival (restricted to the 12 treatment‐comparisons common to OS and PFS/TTP meta‐analyses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Platinum vs non‐platinum regimens (sensitivity analysis 1: excluding selected treatment‐comparisons), Outcome 2 Progression‐free survival/time to progression (restricted to the 12 treatment‐comparisons common to OS and PFS/TTP meta‐analyses)." data-id="CD003374-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Platinum vs non‐platinum regimens (sensitivity analysis 1: excluding selected treatment‐comparisons), Outcome 2 Progression‐free survival/time to progression (restricted to the 12 treatment‐comparisons common to OS and PFS/TTP meta‐analyses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Platinum vs non‐platinum regimens (sensitivity analysis 1: excluding selected treatment‐comparisons), Outcome 3 Objective tumour response rate (assessable participants‐ restricted to the 19 treatment‐comparisons in OS meta‐analyses)." data-id="CD003374-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Platinum vs non‐platinum regimens (sensitivity analysis 1: excluding selected treatment‐comparisons), Outcome 3 Objective tumour response rate (assessable participants‐ restricted to the 19 treatment‐comparisons in OS meta‐analyses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Platinum vs non‐platinum regimens (sensitivity analysis 2: Progression‐free survival vs. time to progression), Outcome 1 Progression‐free survival vs time to progression." data-id="CD003374-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Platinum vs non‐platinum regimens (sensitivity analysis 2: Progression‐free survival vs. time to progression), Outcome 1 Progression‐free survival vs time to progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random effects approach), Outcome 1 Overall survival." data-id="CD003374-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random effects approach), Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random effects approach), Outcome 2 Progression‐free survival/time to progression." data-id="CD003374-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random effects approach), Outcome 2 Progression‐free survival/time to progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003374-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/urn:x-wiley:14651858:media:CD003374:CD003374-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_t/tCD003374-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random effects approach), Outcome 3 Objective tumour response rate (assessable participants)." data-id="CD003374-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random effects approach), Outcome 3 Objective tumour response rate (assessable participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/media/CDSR/CD003374/image_n/nCD003374-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003374-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Platinum‐containing regimens for women with metastatic breast cancer unselected for triple‐negative disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Platinum compared to non‐platinum chemotherapy regimens for women with metastatic breast cancer unselected for triple‐negative disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> platinum<br/> <b>Comparison:</b> non‐platinum chemotherapy regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants (treatment‐ comparisons)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with non‐platinum chemotherapy regimens</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with platinum</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall survival ‐ trials of metastatic breast cancer participants unselected for TNBC </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 1.01<br/> (0.92 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2531 (16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: P = 0.09, I<sup>2</sup>=34% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1,000<br/> (289 to 340)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2‐year risk of death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>540 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>543 per 1,000<br/> (510 to 581)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression‐free survival/time to progression (randomised participants) ‐ trials of metastatic breast cancer participants unselected for TNBC </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of progression or death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.92<br/> (0.84 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1745 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: P = 0.08, I<sup>2</sup>=38% </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>737 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>707 per 1,000<br/> (674 to 740)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2‐year risk of progression or death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>891 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>869 per 1,000<br/> (844 to 893)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective tumour response rate (assessable participants) ‐ trials of metastatic breast cancer participants unselected for TNBC </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>493 per 1,000 <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>547 per 1,000<br/> (512 to 586) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11<br/> (1.04 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3252 (23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity: P = 0.0002, I<sup>2</sup>=58% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Estimated from the average of non‐platinum group Kaplan‐Meier probabilities from the three highest weighted non‐TNBC treatment‐comparisons for this outcome </p> <p><sup>2</sup> Estimated as 1000*(1‐S(t)<sup>HR</sup>) where S(t) is the estimated probability of survival for non‐platinum participants and HR is the pooled hazard ratio (<a href="./references#CD003374-bbs2-0048" title="DaviesHT . Interpreting measures of treatment effect. Hospital Medicine1998;59(6):499‐501. ">Davies 1998</a>) </p> <p><sup>3</sup> Quality of evidence for OS was not downgraded for blinding because this outcome is unlikely to be affected by non‐blinding. </p> <p><sup>4</sup> Downgraded quality of evidence one level for 'indirectness' because this outcome is a surrogate endpoint of questionable validity for assessing the more important outcome of OS in the context of metastatic breast cancer (<a href="./references#CD003374-bbs2-0045" title="BurzykowskiT , BuyseM , Piccart‐GebhartMJ , SledgeG , CarmichaelJ , LückHJ , et al. Evaluation of tumor response, disease control, progression‐free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology2008;26(12):1987‐92. ">Burzykowski 2008</a>) </p> <p><sup>5</sup> Estimated from all 23 non‐TNBC treatment‐comparisons in the review </p> <p><sup>6</sup> Downgraded quality of evidence one level for 'inconsistency' because there was substantial evidence of heterogeneity across studies (P &lt; 0.05) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Platinum‐containing regimens for women with metastatic breast cancer unselected for triple‐negative disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003374-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Platinum‐containing regimens for women with metastatic triple‐negative breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Platinum compared to non‐platinum chemotherapy regimens for women with metastatic triple‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic triple‐negative breast cancer (mTNBC)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> platinum<br/> <b>Comparison:</b> non‐platinum chemotherapy regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants (treatment‐ comparisons)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with non‐platinum chemotherapy regimens</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with platinum</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall survival ‐ trials of mTNBC participants</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.75<br/> (0.57 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>391 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: P = 0.23, I<sup>2</sup> = 32% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>485 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1,000<br/> (315 to 485)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2‐year risk of death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>655 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1,000<br/> (455 to 655)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Progression‐free survival/time to progression (randomised participants) ‐ trials of mTNBC participants </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1‐year risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.59<br/> (0.49 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>391 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Heterogeneity: P = 0.07, I<sup>2</sup> = 67% </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>894 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>733 per 1,000<br/> (667 to 801)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2‐year risk of death</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>987 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>922 per 1,000<br/> (879 to 955)<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective tumour response rate (assessable participants) ‐ trials of mTNBC participants</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>354 per 1,000<sup>7</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1,000<br/> (400 to 552) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.33<br/> (1.13 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>878 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>6,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity: P = 0.0010, I<sup>2</sup> = 78% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Estimated from the average of non‐platinum group Kaplan‐Meier probabilities from the three TNBC treatment‐comparisons contributing data for pooling on this outcome </p> <p><sup>2</sup> Estimated as 1000*(1‐S(t)<sup>HR</sup>) where S(t) is the estimated probability of survival for non‐platinum participants and HR is the pooled hazard ratio (<a href="./references#CD003374-bbs2-0048" title="DaviesHT . Interpreting measures of treatment effect. Hospital Medicine1998;59(6):499‐501. ">Davies 1998</a>) </p> <p><sup>3</sup> Downgraded quality of evidence one level for 'imprecision' because the confidence interval for the pooled estimate is wide and crosses or nearly crosses unity </p> <p><sup>4</sup> Downgraded quality of evidence one level for 'suspected publication bias' because <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> is a large study with 376 participants but has so far only reported median OS/PFS times. As a consequence, the study did not contribute to the pooled HR estimates for OS or PFS/TTP. The reported median OS/PFS times in <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> were similar between platinum and non‐platinum regimens. Hence, it seems likely that if HRs from <a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> were able to be included in pooled HR estimates, these pooled estimates would be considerably closer to the null. </p> <p><sup>5</sup> Quality of evidence for OS was not downgraded for blinding because this outcome is unlikely to be affected by non‐blinding. </p> <p><sup>6</sup> Downgraded quality of evidence one level for 'indirectness' because this outcome is a surrogate endpoint of questionable validity for assessing the more important outcome of OS in the context of metastatic breast cancer (<a href="./references#CD003374-bbs2-0045" title="BurzykowskiT , BuyseM , Piccart‐GebhartMJ , SledgeG , CarmichaelJ , LückHJ , et al. Evaluation of tumor response, disease control, progression‐free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology2008;26(12):1987‐92. ">Burzykowski 2008</a>) </p> <p><sup>7</sup>Estimated from all five TNBC treatment‐comparisons in the review </p> <p><sup>8</sup> Downgraded quality of evidence one level for 'inconsistency' because there was substantial evidence of heterogeneity across studies (P &lt; 0.05) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Platinum‐containing regimens for women with metastatic triple‐negative breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003374-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Platinum‐containing regimens and toxicity profile</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Platinum compared to non‐platinum chemotherapy regimens for nausea/vomiting, anaemia, hair loss and leukopenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with metastatic breast cancer<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> platinum<br/> <b>Comparison:</b> non‐platinum chemotherapy regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants (treatment‐ comparisons)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with non‐platinum chemotherapy regimens</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with platinum</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Nausea/vomiting* grade 3 or 4 (safety population) by type of platinum agent in platinum regimen </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Carboplatin</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 0.77, 95% CI 0.47 to 1.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1441 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Test for carboplatin/cisplatin subgroup difference: P &lt; 0.0001</p> <p>Heterogeneity among carboplatin studies: P = 0.30, I<sup>2</sup> = 17% </p> <p>Heterogeneity among cisplatin studies: P = 0.010, I<sup>2</sup> = 32% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1,000<br/> (59 to 101) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Cisplatin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 2.65, 95% CI 2.10 to 3.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1747 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1,000<br/> (167 to 266) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Anaemia grade 3 or 4 (safety population) by type of platinum agent in platinum regimen</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Carboplatin</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 1.72, 95% CI 1.10 to 2.70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1441 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Test for carboplatin/cisplatin subgroup difference: P = 0.02</p> <p>Heterogeneity among carboplatin studies: P = 0.67, I<sup>2</sup> = 0% </p> <p>Heterogeneity among cisplatin studies: P = 0.50, I<sup>2</sup> = 0% </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1,000<br/> (36 to 89) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Cisplatin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 3.72, 95% CI 2.36 to 5.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1644 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕</p> <p>HIGH</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1,000<br/> (78 to 194) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hair loss grade 3 or 4 (safety population)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Carboplatin or cisplatin</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 1.41, 95% CI 1.26 to 1.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1452 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Test for carboplatin/cisplatin subgroup difference: P = 0.23</p> <p>Heterogeneity: P = 0.10, I<sup>2</sup> = 40% </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>264 per 1,000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>372 per 1,000<br/> (333 to 417) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Leukopenia** grade 3 or 4 (safety population)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Carboplatin or cisplatin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 1.38, 95% CI 1.21 to 1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3176 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Test for carboplatin/cisplatin subgroup difference: P = 0.22</p> <p>Heterogeneity: P = 0.0002, I<sup>2</sup> = 60% </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>179 per 1,000 <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>247 per 1,000 (217 to 281)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR:</b> Hazard ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Estimated from all treatment‐comparisons (cisplatin and carboplatin) contributing data for pooling for this outcome </p> <p><sup>2</sup> Downgraded quality of evidence one level for 'imprecision' because the confidence interval for the pooled estimate is wide and does not rule out 'no effect' </p> <p><sup>3</sup> Downgraded quality of evidence one level for 'inconsistency' because there was substantial evidence of heterogeneity across studies (P &lt; 0.05) </p> <p>*data on vomiting was included if data on nausea/vomiting was reported separately</p> <p>**data on neutropenia was included if data on leukopenia was not reported</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Platinum‐containing regimens and toxicity profile</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003374-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Platinum agents</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Generic name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other names</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, Nealorin, Novoplatinum, Paraplat, Paraplatin AQ, Paraplatin, Paraplatine, Platinwas, Ribocarbo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abiplatin, Blastolem, Briplatin,CACP, CDDP, cis‐DDP, cis‐diamminedichloridoplatinum, cis‐diamminedichloro platinum (II), cis‐diamminedichloroplatinum, Cis‐dichloroammine Platinum (II), Cismaplat, Cisplatina, cis‐platinous diamine dichloride, cis‐platinum II diamine dichloride, cis‐platinum II, cis‐platinum, Cisplatyl, Citoplatino, Citosin, CPDD, Cysplatyna, DDP, DDP, Lederplatin, Metaplatin, Neoplatin, PDD, Peyrone's Chloride, Peyrone's Salt, Placis, Platamine, Platiblastin, Platiblastin‐S, Platinex, Platinol‐ AQ, Platinol, Platinol‐AQ VHA Plus, Platinol‐AQ, Platinoxan, platinum diamminodichloride, Platiran, Platistin, Platosin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxaliplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ai Heng, Aiheng, diaminocyclohexane oxalatoplatinum, oxalatoplatin, oxalatoplatinum, oxaliplatine, Eloxatin, Dacotin, Dacplat, Eloxatine, 1‐OHP, L‐OHP, oxaliplatin medac </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Platinum agents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003374-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Chemotherapeutic Agents (adapted from Table 1.1 in The Chemotherapy Source Book)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of Agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Action</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Includes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agents that damage the DNA template</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: nitrogen mustards</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cyclophosphamide, melphalan, ifosfamide, chlorambucil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: nitrosureas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>carmustine (BCNU), lomustine (CCNU)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by alkylation: other agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>thiotepa, mitomycin C</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by platinum coordination cross‐linking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cisplatin, carboplatin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>doxorubicin, daunorubicin, mitoxantrone, idarubicin, epirubicin, amsacrine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>podophyllotoxins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>etoposide, teniposide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by intercalation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dactinomycin, mithramycin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>by uncertain mechanisms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bleomycin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spindle poisons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vinca alkaloids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vincristine, vinblastine, vendesine, vinorelbine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>taxanes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>taxol, taxotere</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antimetabolites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>thymidylate synthase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐fluorouracil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>dihydrofolate reductase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>methotrexate</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Chemotherapeutic Agents (adapted from Table 1.1 in The Chemotherapy Source Book)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003374-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of treatment‐comparisons included in meta‐analyses by subgroup and three outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subgroup</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment‐</b> </p> <p><b>comparisons</b> </p> <p><b>N</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall</b> </p> <p><b>survival</b> </p> <p><b>n (% of N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression</b> </p> <p><b>‐free</b> </p> <p><b>survival/time to</b> </p> <p><b>progression</b> </p> <p><b>n (% of N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objective</b> </p> <p><b>response</b> </p> <p><b>rate</b> </p> <p><b>n (% of N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall:</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (68%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (57%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of platinum agent in platinum arm:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cisplatin in platinum arm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (65%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (65%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carboplatin in platinum arm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (80%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxaliplatin in platinum arm</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of regimen comparison:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regimen A + platinum agent vs regimen A</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (67%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (67%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regimen A + platinum agent vs regimen B</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (72%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (56%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single agent platinum vs regimen C</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>First‐line therapy:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First‐line therapy for &gt; 80% of participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (75%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (55%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Second‐ or third‐line therapy for ≥ 20% of participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (63%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant selection for mTNBC:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with mTNBC</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (60%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (60%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants unselected for mTNBC</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (70%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (57%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anthracycline in regimens:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No anthracycline in platinum or non‐platinum regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (78%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (61%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum + anthracycline vs non‐platinum + anthracycline regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (67%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum + anthracycline vs non‐platinum + non‐anthracycline regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (25%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Taxane in regimens:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No taxane in platinum or non‐platinum regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (53%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (53%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum + taxane vs non‐platinum + taxane regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (50%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum + non‐taxane vs non‐platinum + taxane regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (80%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (80%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trastuzumab in regimens:</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trastuzumab in platinum or non‐platinum regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (65%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (54%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platinum + trastuzumab vs non‐platinum + trastuzumab regimens</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (100%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (100%)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of treatment‐comparisons included in meta‐analyses by subgroup and three outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003374-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of regimens included in the analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trials ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arm 1 (platinum‐containing)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arm 2 (control)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>First‐line therapy for &gt; 80% of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Majority participants anthracycline‐naive</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen A</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0002" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + Cis (epirubicin+cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi (epirubicin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0003" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + Cis + LND (epirubicin+cisplatin+lonidamine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + LND (epirubicin + lonidamine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0004" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple‐negative. European Journal of Cancer Supplements. 2009; Vol. 7, issue 3:18‐19. ">Bhattacharyya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endoxan 50 mg per day at 10 am and methotrexate 2.5 mg twice a day at 9 am and 5 pm and with 'cisplatinum' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endoxan 50 mg per day at 10 am and methotrexate 2.5 mg twice a day at 9 am and 5 pm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C + Cb (Cetuximab + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C (Cetuximab with carboplatin added after progression)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0009" title="CostanzaME , WeissRB , HendersonIC , NortonL , BerryDA , CirrincioneC , et al. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study‐‐Cancer and Leukemia Group B 8642. Journal of Clinical Oncology1999;17(5):1397‐406. ">Costanza 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBDA + CAF (carboplatin + cycloheximide + doxorubicin + fluorouracil + methotrexate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAF (cycloheximide + doxorubicin + fluorouracil)</p> <p>(methotrexate substituted after total doxorubicin ‐ 540 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0015" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCb (paclitaxel + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pw (paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0021" title="NielsenD , DombernowskyP , LarsenSK , HansenOP , SkovsgaardT . Epirubicin or epirubicin and cisplatin as first‐line therapy in advanced breast cancer. A phase III study. Cancer Chemotherapy &amp; Pharmacology2000;46(6):459‐66. RybergM , NielsenD , SkovsgaardT , HansenJ , JensenBV , DombernowskyP . Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. Journal of Clinical Oncology1998;16(11):3502‐8. ">Nielsen 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + Cis (epirubicin + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi (epirubicin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0022" title="RobertN , Leyland‐JonesB , AsmarL , BeltR , IlegboduD , LoeschD , et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER‐2‐overexpressing metastatic breast cancer. Journal of Clinical Oncology2006;24(18):2786‐92. ">Robert 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TPC (trastuzumab + paclitaxel + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TP (trastuzumab + paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0026" title="ForbesJF , PienkowskiT , ValeroV , EiermannW , VonMinckwitzG , MartinM , et al. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first‐line in HER2 positive metastatic breast cancer (MBC). Journal of Clinical Oncology2006;24(Supplement):18S. NCT00047255 . Docetaxel and trastuzumab with or without carboplatin in treating women with HER2‐positive breast cancer. clinicaltrials.gov/ct2/show/NCT00047255 (accessed 13 April 2016). ValeroV , ForbesJ , PegramMD , PienkowskiT , EiermannW , VonMinckwitzG , et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first‐line chemotherapy for patients with HER2‐gene‐amplified metastatic breast cancer (BCIRG 007 Study): Two highly active therapeutic regimens. Journal of Clinical Oncology2011;29(2):149‐56. ">Valero 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TCH (trastuzumab + docetaxel + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TH (trastuzumab + docetaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen B</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(pemetrexed + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(vinorelbine + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0006" title="CocconiG , BisagniG , BacchiM , BoniC , BartolucciR , CeciG , et al. Cisplatin and etoposide as first‐line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology1991;9(4):664‐9. ">Cocconi 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MPEPIV(a) or MPEMi (b) (a<i>:</i> methotrexate, leucovorin, cisplatin, epirubicin, vincristine; b: methotrexate, leucovorin, cisplatin, etoposide, mitomycin) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMF (cyclophosphamide, methotrexate, fluorouracil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0007" title="CocconiG , BellaM , BartolucciR , BasurtoC , ColozzaM , IndelliM . Continuous CMF compared to a short chemotherapy using cisplatin‐containing combinations in metastatic breast carcinoma. A prospective randomized study. Annals of Oncology1996;7(Suppl 5):22. ">Cocconi 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Etop + Cis (etoposide + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMF (cyclophosphamide, methotrexate, fluorouracil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0008" title="CocconiG , BisagniG , BellaM , AcitoL , AnastasiP , CarpiA , et al. Comparison of CMF (cyclophosphamide, methotrexate, and 5‐fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. American Journal of Clinical Oncology1999;22(6):593‐600. ">Cocconi 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PE + CMF + AL (cisplatin + etoposide + doxorubicin + cyclophosphamide, methotrexate + fluorouracil, lecovorin + allopurinol) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMF (cyclophosphamide, methotrexate, fluorouracil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0010" title="CreaganET , GreenSJ , AhmannDL , IngleJN , EdmonsonJH , MarschkeRF‐J . A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5‐ fluorouracil, prednisone in patients with advanced breast cancer. Journal of Clinical Oncology1984;2(11):1260‐5. ">Creagan 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CFP + CAP (cyclophosphamide + doxorubicin + cis‐dichlordiammine + CFP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CFP (cyclophosphamide + fluorouracil + prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0011" title="DelalogeS , Tubiana‐HulinM , WardleyA , DelMastroL , SantoroA , ZambelliA , et al. A multistep randomized phase II/III trial comparing Oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN) + FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results. Journal of Clinical Oncology. 2004; Vol. 22 Supplement:14S. ">Delaloge 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OXA (oxaliplatin + 5‐flurouracil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIN (vinorelbine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0012" title="EisenT , SmithIE , DeBoerR , EllisPA . A randomised phase II trial of infusional 5‐FU and epirubicin with cyclophosphamide versus cisplatin in advanced breast cancer. Breast Cancer Research &amp; Treatment1997;46(1):94. EisenT , SmithIE , JohnstonS , EllisPA , PrendivilleJ , SeymourMT , et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. Journal of Clinical Oncology1998;16(4):1350‐7. ">Eisen 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EcisF (5‐flurouracil + epirubicin + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EcycloF (5‐flurouracil + epirubicin + cyclophosphamide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0013" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first‐line treatment of metastatic triple‐negative breast cancer. Annals of Oncology2013;24(5):1219‐25. ">Fan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TP (docetaxel + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TX (docetaxel + capecitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + Pcb (epirubicin + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epi + P (epirubicin + paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y (54%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCb (paclitaxel + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDoc (docetaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(cisplatin + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(paclitaxel + gemcitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0018" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP‐16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002; Vol. 13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639‐44. ">Icli 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Etop + Cis (etoposide + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P (paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0019" title="KolaricK , VukasD , RothA , PotrebicaV , CervekJ , CerarO . Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report. Tumori1985;71:159‐65. ">Kolaric 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAP (cyclophosphamide + doxorubicin + platinum)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMFVP (cyclophosphamide + methotrexate + 5‐fluorouracil + vincristine + prednisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0020" title="KolaricK , VukasD , PotrebicaV . Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5‐fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. Tumori1989;75:132‐6. ">Kolaric 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAP (cyclophosphamide + doxorubicin +platinum)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FAC (5‐flurouracil + doxorubicin +</p> <p>cyclophosphamide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0023" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCis (gemcitabine + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemVin (gemcitabine + vinorelbine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0024" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCis (gemcitabine + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCap (gemcitabine + capecitabine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0027" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCis (gemcitabine + cisplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemPac (gemcitabine + paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0028" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemCarb (gemcitabine + carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GemPac (gemcitabine + paclitaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Single agent platinum vs regimen C</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C (carboplatin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D (docetaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of regimens included in the analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003374-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of outcomes for included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Extractable OS data for HR estimation<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median OS time<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Extractable PFS/TTP data for HR estimation<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median PFS/TTP time<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment‐related deaths</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade III &amp; IV Toxicity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Accrual<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen A</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0002" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Nephrotoxicity</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>185</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0003" title="BerrutiA , BitossiR , GorzegnoG , BottiniA , AlquatiP , DeMatteisA , et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of Clinical Oncology2002;20(20):4150‐9. ">Berruti 2002 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Nephrotoxicity</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0004" title="BhattacharyyaGS , BasuS , AgarwalV , MalhotraH , PareekhPM , BabuKG , et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple‐negative. European Journal of Cancer Supplements. 2009; Vol. 7, issue 3:18‐19. ">Bhattacharyya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>126</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0005" title="CareyLA , RugoHS , MarcomPK , MayerEL , EstevaFJ , MaCX , et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple‐negative breast cancer. Journal of Clinical Oncology2012;30(21):2615‐23. NCT00232505 . Cetuximab with or without carboplatin in treating women with estrogen receptor‐negative, progesterone receptor‐negative metastatic breast cancer. clinicaltrials.gov/show/NCT00232505 (accessed 13 April 2016). ">Carey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not extractable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0009" title="CostanzaME , WeissRB , HendersonIC , NortonL , BerryDA , CirrincioneC , et al. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study‐‐Cancer and Leukemia Group B 8642. Journal of Clinical Oncology1999;17(5):1397‐406. ">Costanza 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>221</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0015" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0021" title="NielsenD , DombernowskyP , LarsenSK , HansenOP , SkovsgaardT . Epirubicin or epirubicin and cisplatin as first‐line therapy in advanced breast cancer. A phase III study. Cancer Chemotherapy &amp; Pharmacology2000;46(6):459‐66. RybergM , NielsenD , SkovsgaardT , HansenJ , JensenBV , DombernowskyP . Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. Journal of Clinical Oncology1998;16(11):3502‐8. ">Nielsen 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0022" title="RobertN , Leyland‐JonesB , AsmarL , BeltR , IlegboduD , LoeschD , et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER‐2‐overexpressing metastatic breast cancer. Journal of Clinical Oncology2006;24(18):2786‐92. ">Robert 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0026" title="ForbesJF , PienkowskiT , ValeroV , EiermannW , VonMinckwitzG , MartinM , et al. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first‐line in HER2 positive metastatic breast cancer (MBC). Journal of Clinical Oncology2006;24(Supplement):18S. NCT00047255 . Docetaxel and trastuzumab with or without carboplatin in treating women with HER2‐positive breast cancer. clinicaltrials.gov/ct2/show/NCT00047255 (accessed 13 April 2016). ValeroV , ForbesJ , PegramMD , PienkowskiT , EiermannW , VonMinckwitzG , et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first‐line chemotherapy for patients with HER2‐gene‐amplified metastatic breast cancer (BCIRG 007 Study): Two highly active therapeutic regimens. Journal of Clinical Oncology2011;29(2):149‐56. ">Valero 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Regimen A + platinum vs regimen B</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0001" title="AmadoriD , CarrascoE , RoeselS , LabiancaR , UzielyB , SoldatenkovaV , et al. A randomized phase II non‐comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline‐ and taxane‐pretreated advanced breast cancer patients. International Journal of Oncology2013;42(5):1778‐85. AmadoriD , LaTorreI , CarrascoEM , RoeselS , LabiancaR , Moreau‐DonnetV , et al. A randomized phase II study of pemetrexed‐carboplatin and gemcitabine‐vinorelbine in patients with anthracycline‐ and taxane‐pretreated advanced breast cancer. Journal of Clinical Oncology2011;29(15 Suppl):1051‐1051. NCT00325234 . Pemetrexed‐carboplatin and gemcitabine‐vinorelbine in advanced breast cancer. clinicaltrials.gov/ct2/show/results/NCT00325234 (accessed 13 April 2016). ">Amadori 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0006" title="CocconiG , BisagniG , BacchiM , BoniC , BartolucciR , CeciG , et al. Cisplatin and etoposide as first‐line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology1991;9(4):664‐9. ">Cocconi 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0008" title="CocconiG , BisagniG , BellaM , AcitoL , AnastasiP , CarpiA , et al. Comparison of CMF (cyclophosphamide, methotrexate, and 5‐fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. American Journal of Clinical Oncology1999;22(6):593‐600. ">Cocconi 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0007" title="CocconiG , BellaM , BartolucciR , BasurtoC , ColozzaM , IndelliM . Continuous CMF compared to a short chemotherapy using cisplatin‐containing combinations in metastatic breast carcinoma. A prospective randomized study. Annals of Oncology1996;7(Suppl 5):22. ">Cocconi 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not extractable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0010" title="CreaganET , GreenSJ , AhmannDL , IngleJN , EdmonsonJH , MarschkeRF‐J . A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5‐ fluorouracil, prednisone in patients with advanced breast cancer. Journal of Clinical Oncology1984;2(11):1260‐5. ">Creagan 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0011" title="DelalogeS , Tubiana‐HulinM , WardleyA , DelMastroL , SantoroA , ZambelliA , et al. A multistep randomized phase II/III trial comparing Oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN) + FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results. Journal of Clinical Oncology. 2004; Vol. 22 Supplement:14S. ">Delaloge 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not extractable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0012" title="EisenT , SmithIE , DeBoerR , EllisPA . A randomised phase II trial of infusional 5‐FU and epirubicin with cyclophosphamide versus cisplatin in advanced breast cancer. Breast Cancer Research &amp; Treatment1997;46(1):94. EisenT , SmithIE , JohnstonS , EllisPA , PrendivilleJ , SeymourMT , et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. Journal of Clinical Oncology1998;16(4):1350‐7. ">Eisen 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0013" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first‐line treatment of metastatic triple‐negative breast cancer. Annals of Oncology2013;24(5):1219‐25. ">Fan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0014" title="FountzilasG , KalofonosHP , BafaloukosD , PapakostasP , KosmidisP , GogasH , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2002;13(Suppl 5):46‐69. FountzilasG , KalofonosHP , DafniU , PapadimitriouC , BafaloukosD , PapakostasP , et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2004;15(10):1517‐26. ">Fountzilas 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0016" title="FountzilasG , DafniU , DimopoulosMA , KoutrasA , SkarlosD , PapakostasP , et al. A randomized phase III study comparing three anthracycline‐free taxane‐based regimens, as first‐line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment2009;11:87‐99. ">Fountzilas 2009 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>212</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0017" title="HuXC , ZhangJ , XuBH , CaiL , RagazJ , WangZH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line therapy for metastatic triple‐negative breast cancer (CBCSG006): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncology2015;16(4):436‐46. NCT01287624 . Gemcitabine plus cisplatin versus gemcitabine plus paclitaxel in triple negative breast cancer (TNBC). clinicaltrials.gov/ct2/show/NCT01287624 (accessed 13 April 2016). ">Hu 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0018" title="IcliF , AkbulutH , UnerA , BulentY , AltinbasM , BaltaliE , et al. Paclitaxel (T) vs cisplatin + VP‐16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. Annals of Oncology2002; Vol. 13:47. IcliF , AkbulutH , UnerA , YalcinB , BaltaliE , AltinbasM , et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer2005;92:639‐44. ">Icli 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0019" title="KolaricK , VukasD , RothA , PotrebicaV , CervekJ , CerarO . Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report. Tumori1985;71:159‐65. ">Kolaric 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Nephrotoxicity</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0020" title="KolaricK , VukasD , PotrebicaV . Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5‐fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. Tumori1989;75:132‐6. ">Kolaric 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0023" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0024" title="NCT00480597 . Gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer. clinicaltrials.gov/ct2/show/NCT00480597 (accessed 13 April 2016). StemmlerHJ , DiGioiaD , FreierW , TessenHW , GitschG , JonatW , et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer2011;104(7):1071‐8. ">Stemmler 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0027" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Nephrotoxicity</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0028" title="NCT00191854 . Gemcitabine combinations in metastatic breast cancer (MBC), 1st Line. clinicaltrials.gov/ct2/show/results/NCT00191854 (accessed 13 April 2016). XuB , JiangZ , KimSB , YuS , FengJ , MalzynerA , et al. Biweekly gemcitabine‐paclitaxel, gemcitabine‐carboplatin, or gemcitabine‐cisplatin as first‐line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer2011;18(3):203‐12. ">Xu 2011 B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> <p>Nephrotoxicity</p> <p>Anaemia</p> <p>Hair loss</p> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Single agent platinum vs regimen C</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003374-bbs2-0025" title="NCT00532727 . Triple negative breast cancer trial (TNT). clinicaltrials.gov/show/NCT00532727 (accessed 13 April 2016). TuttA , EllisP , KilburnL , GilettC , PinderS , AbrahamJ , et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Research2015;75(9 Supplement):S3‐01. TuttA , EllisP , KilburnLS . The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced trip‐negative or BRCA1/2 breast cancer. Thirty‐Seventh Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 9‐13, 2014; San Antonio, TX. 2014; Vol. 75:S3‐1. ">Tutt 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>376</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>1</sup> Sufficient data reported to estimate a HR for pooling as outlined by <a href="./references#CD003374-bbs2-0063" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815‐34. ">Parmar 1998</a> and <a href="./references#CD003374-bbs2-0069" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8(1):1. ">Tierney 2007</a>; this includes Kapalan‐Meier curve, HR and standard error/confidence interval or logrank statistics </p> <p><sup>2</sup> Trials that did not explicitly report median time were classified as NR here regardless of estimable median time from Kaplan‐Meier curve </p> <p><sup>3</sup> Accrual numbers represent the maximum numbers of participants in the trial (not study) that were included in the analyses of OS, PFS/TTP or OR (assessable participants). </p> <p>*NR = not reported, DU = deaths unexplained, Y = data reported.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of outcomes for included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/full#CD003374-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003374-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Treatment‐comparisons assessing patients with mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.57, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Treatment‐comparisons assessing patients unselected for mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.92, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.78, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Treatment‐comparisons assessing patients with mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.49, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Treatment‐comparisons assessing patients unselected for mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.84, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.08, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Treatment‐comparisons assessing patients with mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.13, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Treatment‐comparisons assessing patients unselected for mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [1.04, 1.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 1: by treatment‐comparisons assessing mTNBC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003374-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 2: by type of regimen comparison)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Regimen A + platinum agent vs regimen A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.93, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Regimen A + platinum agent vs regimen B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival / time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.78, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Regimen A+platinum agent vs regimen A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.78, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Regimen A+platinum agent vs regimen B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.74, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.08, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Regimen A + platinum agent vs regimen A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.01, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Regimen A + platinum agent vs regimen B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.12, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Single agent platinum vs regimen C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.66, 1.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 2: by type of regimen comparison)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003374-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.80, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.78, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.76, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.75, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.08, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.24, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.86, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Oxaliplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.48, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Treatment‐related death (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.73, 2.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.59, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.57, 6.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Oxaliplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Nausea/vomiting (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [1.69, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [2.10, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.47, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Nephrotoxicity (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [0.86, 10.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.46 [0.86, 13.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.07, 36.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Anaemia (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.61 [1.90, 3.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.72 [2.36, 5.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.10, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Hair loss (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.26, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.15, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.28, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Leukopenia (safety population) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.21, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Cisplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.23, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Carboplatin in platinum arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.07, 1.50]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 3: by type of platinum agent in platinum arm)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003374-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 4: by first‐line therapy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 First‐line therapy for &gt; 80% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.90, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Second‐ or third‐line therapy for ≥20% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.73, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.78, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 First‐line therapy for &gt; 80% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Second‐ or third‐line therapy for ≥20% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.65, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.08, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 First‐line therapy for &gt; 80% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.06, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Second‐ or third‐line therapy for ≥20% of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.02, 1.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 4: by first‐line therapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003374-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 5 by anthracycline in regimens)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No anthracycline in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Platinum + anthracycline vs non‐platinum + anthracycline regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.88, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Platinum + anthracycline vs non‐platinum + non‐anthracycline regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.78, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.78, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 No anthracycline in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.73, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Platinum+anthracycline vs non‐platinum+anthracycline regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.86, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Platinum+anthracycline vs non‐platinum+non‐anthracycline regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.75, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.08, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No anthracycline in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.02, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Platinum+anthracycline vs non‐platinum+anthracycline regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.97, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Platinum+anthracycline vs non‐platinum+non‐anthracycline regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.28, 1.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 5 by anthracycline in regimens)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003374-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 6: by taxane in regimens)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No taxane in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.93, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Platinum + taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Platinum + non‐taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.69, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival / time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.78, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 No taxane in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.80, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Platinum + taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Platinum + non‐taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.69, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.08, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No taxane in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.15, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Platinum + taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.90, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Platinum + non‐taxane vs non‐platinum + taxane regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>924</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.94, 1.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 6: by taxane in regimens)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003374-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 7: by trastuzumab in regimens)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No trastuzumab in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.88, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Platinum + trastuzumab vs non‐platinum + trastuzumab regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.78, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 No trastuzumab in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.76, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Platinum+trastuzumab vs non‐platinum+trastuzumab regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.75, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.08, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No trastuzumab in platinum or non‐platinum regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.07, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Platinum+trastuzumab vs non‐platinum+trastuzumab regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.99, 1.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Platinum vs non‐platinum regimens (subgroup analysis 7: by trastuzumab in regimens)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003374-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 1: excluding selected treatment‐comparisons)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival (restricted to the 12 treatment‐comparisons common to OS and PFS/TTP meta‐analyses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival/time to progression (restricted to the 12 treatment‐comparisons common to OS and PFS/TTP meta‐analyses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.73, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Objective tumour response rate (assessable participants‐ restricted to the 19 treatment‐comparisons in OS meta‐analyses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.05, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 1: excluding selected treatment‐comparisons)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003374-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 2: Progression‐free survival vs. time to progression)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Progression‐free survival vs time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.78, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Progression‐free survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Time to progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>HR (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.69, 0.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 2: Progression‐free survival vs. time to progression)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003374-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random effects approach)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.87, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Treatment‐comparisons assessing patients with mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.51, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Treatment‐comparisons assessing patients unselected for mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.90, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival/time to progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.76, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Treatment‐comparisons assessing patients with mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.38, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Treatment‐comparisons assessing patients unselected for mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.85, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Objective tumour response rate (assessable participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.05, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Treatment‐comparisons assessing patients with mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.04, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Treatment‐comparisons assessing patients unselected for mTNBC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.01, 1.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Platinum vs non‐platinum regimens (sensitivity analysis 3: Analyses 1 repeated but with random effects approach)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003374.pub4/references#CD003374-tbl-0018">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003374.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003374-note-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003374-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003374-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD003374-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD003374-note-0001">日本語</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003374-note-0012">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003374\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003374\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003374\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003374\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003374\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003374.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003374.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003374.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003374.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003374.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729509725"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003374.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729509729"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003374.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918edea01f38bd65',t:'MTc0MDcyOTUxMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 